

## Karen J. Wiley Wernli, Ph.D. | Curriculum Vitae

### BIOGRAPHICAL AND EDUCATIONAL INFORMATION

*Email* Karen.J.Wernli@kp.org

*Mobile* 206.235.8564

*Desk* 206.287.2934

*Fax* 206.287.2871

*Address* Kaiser Permanente Washington Health Research Institute  
1730 Minor Avenue, Suite 1360  
Seattle, WA 98101

*Website:* <https://www.kpwashingtonresearch.org/our-research/our-scientists/Wernli-Karen>

*Citizenship:* USA, Switzerland

### **Languages**

English – native language

German and Spanish – speak, read, and write with basic competency

### **Education**

1995 BS, Animal Physiology and Neuroscience, University of California, San Diego

1998 MS, Epidemiology, University of Texas, School of Public Health, Houston

2006 PhD, Epidemiology, University of Washington, School of Public Health, Seattle

### **PROFESSIONAL POSITIONS**

1995-1996 Staff Research Associate, University of California, San Diego, La Jolla, California

1997-1998 Research Assistant, University of Texas, MD Anderson Cancer Center, Houston, Texas

1998 Comparative Health Intern, London School of Hygiene and Tropical Medicine, London, UK

1999-2000 Study Coordinator, University of Washington, Seattle, Washington

2000-2002 Project Coordinator, Fred Hutchinson Cancer Research Center, Seattle, Washington

2002-2006 Pre-doctoral Research Associate, Fred Hutchinson Cancer Research Center, Seattle, Washington

2007-2009 Post-doctoral Research Associate, Fred Hutchinson Cancer Research Center, Seattle, Washington

2009-2011 Research Associate II, Kaiser Permanente Washington Health Research Institute, Seattle, Washington

2011-2012 Research Associate III, Kaiser Permanente Washington Health Research Institute, Seattle, Washington

- 2012-2016 Assistant Investigator, Kaiser Permanente Washington Health Research Institute, Seattle, Washington
- 2012-2017 Affiliate Assistant Professor, University of Washington, Department of Health Services, Seattle, Washington
- 2016-2022 Associate Scientific Investigator, Kaiser Permanente Washington Health Research Institute, Seattle, Washington
- 2017-2024 Affiliate Associate Professor, University of Washington, Department of Health Systems and Population Health, Seattle, Washington
- 2019-2024 Affiliate Associate Professor, University of Washington, Department of Epidemiology, Seattle, Washington
- 2020-2022 Associate Professor, Kaiser Permanente School of Medicine, Department of Health System Science
- 2022- Senior Scientific Investigator, Kaiser Permanente Washington Health Research Institute, Seattle, WA
- 2022- Professor, Bernard J. Tyson Kaiser Permanente School of Medicine, Department of Health System Science, Pasadena, California
- 2024- Affiliate Professor, University of Washington, Department of Health Systems and Population Health, Seattle, Washington
- 2024- Affiliate Professor, University of Washington, Department of Epidemiology, Seattle, Washington

**PROFESSIONAL HONORS & AWARDS**

- 1997-1998 Grossmont Hospital Student Scholarship
- 1997-1998 National Cancer Institute, Cancer Prevention Fellow Short-Term Intern
- 2003-2006 National Institute for Environmental Health Sciences, Environmental and Molecular Epidemiology Fellow, Pre-Doctoral Fellow
- 2008 Prevent Cancer Foundation and American Society of Preventive Oncology Cancer Prevention Research Fellowship
- 2008-2010 National Institute of Health, Loan Repayment Program Awardee
- 2010-2013 K12 Comparative Effectiveness Research Scholar
- 2011-2012 National Institute of Health, Loan Repayment Program Renewal
- 2016 American Society of Preventive Oncology, Top submitted 16 abstracts
- 2018 Nominee, Outstanding Staff Mentoring Award, Kaiser Permanente Washington Health Research Institute
- 2019 American Society of Preventive Oncology, Top submitted 14 abstracts

- 2019 Nominee, Outstanding Faculty Mentoring Award, Kaiser Permanente Washington Health Research Institute
- 2020 Nominee, Michael Von Korff Distinguished Service Award
- 2020 National Cancer Institute, Multilevel Intervention Training Institute Fellow
- 2023 University of North Carolina, Chapel Hill, Department of Epidemiology, Robert C. Millikan Speaker
- 2023 Recipient, Outstanding Staff Mentoring Award, Kaiser Permanente Washington Health Research Institute

**MEMBERSHIPS**

- 2005- Society for Epidemiologic Research
- 2007- American Association for Cancer Research
- 2007- American Society for Preventive Oncology
- 2010- AcademyHealth
- 2014-2022 American Society for Clinical Oncology

**ORGANIZATIONAL SERVICE**

- 2012-2014 Lead, Clinical Prevention Research Group (CPRG), Group Health Research Institute
- 2013-2015 Member and Co-Chair, Scientific Policy Committee (SPC), Group Health Research Institute
- 2014 Member, GHRI Representative, Group Health Population Health Management Initiative
- 2014 Member, Faculty Search Committee, Group Health Research Institute
- 2016-2021 Member, Kaiser Permanente Washington Institutional Review Board
- 2018-2019 Member and Co-Chair, Scientific Advisory Committee (SAC), Kaiser Permanente Washington Health Research Institute
- 2018 Member, Equity Team, Kaiser Permanente Washington Health Research Institute
- 2018 Co-organizer, High School Student Outreach Day, Kaiser Permanente Washington Health Research Institute
- 2020 Member, Institute Steering Committee, Kaiser Permanente Washington Health Research Institute
- 2026- Member, Scientific Advisory Committee, Kaiser Permanente Washington Health Research Institute

## **OTHER PROFESSIONAL SERVICE**

### ***Professional Society Activities***

- 2008-2009 Co-Chair, American Society for Preventive Oncology, Young Investigators Workshop, "Transitioning from Mentored Scientist to Career Independence"
- 2012-2013 Co-Chair, American Society for Preventive Oncology, International Cancer Screening Workshop, "Undertaking Cancer Research in International Settings"
- 2016-2017 Member, Program Planning Committee, American Society of Preventive Oncology, 41<sup>st</sup> Annual Meeting in Seattle, WA (Mar 11-14, 2017)
- 2018, 2019 Poster Judge, American Society for Preventive Oncology Annual Meeting
- 2022- Member, American Cancer Society Lung Cancer Roundtable, Lung Cancer Early Detection Implementation Strategies Task Group
- 2022-2024 Chair, American Society for Preventive Oncology, Survivorship and Health Outcomes/Comparative Effectiveness Research Special Interest Group
- 2023-2024 Member, Program Planning Committee, American Society for Preventive Oncology, 48<sup>th</sup> Annual Meeting in Chicago, IL (Mar 17-20, 2024)
- 2024-2025 Co-Chair, Program Planning Committee, American Society for Preventive Oncology, 49<sup>th</sup> Annual Meeting in Philadelphia, PA, (Apr 5-8, 2025)
- 2024- Member, International Cancer Screening Network, Lung Cancer Screening Workgroup

### ***Other Committee Work and Service***

- 1997-1998 Student Representative, Master of Science, University of Texas, School of Public Health
- 2002-2003 Member, Epidemiology Seminar Committee, University of Washington, School of Public Health
- 2004-2005 Member, Department of Epidemiology Student Representative, University of Washington, School of Public Health
- 2013-2015 Member, Research Committee, University of Washington, Department of Health Services
- 2016-2020, 2023- Volunteer, Seattle King County Medical Clinic
- 2024- Member, Scientific and Medical Advisory Board, Cactus Cancer Society

## **SPECIAL NATIONAL & INTERNATIONAL RESPONSIBILITIES**

- 6/2012 Ad Hoc Member, NIH Small Grants Program for Cancer Epidemiology
- 9/2012 Ad Hoc Member, Ministry of Health, Singapore, Singapore
- 2/2013 Ad Hoc Member, Susan G. Komen Puget Sound Chapter
- 3/2013 Ad Hoc Member, NIH Small Grants Program for Cancer Epidemiology
- 11/2013 Ad Hoc Member, Maryland Health Technology Assessment

8/2014	Ad Hoc Member, Patient-Centered Outcomes Research Institute, Comparative Effectiveness Research Panel
2/2016	Ad Hoc Member, Ministry of Health, Singapore, Singapore
6/2016	Ad Hoc Member, NIH Health Services Organization and Delivery Study Section
9/2016	Ad Hoc Member, Research Council of Norway
6/2017	Ad Hoc Member, NIH Health Services Organization and Delivery Study Section
1/2018	Ad Hoc Member, American Cancer Society Cancer Control and Prevention: Health Policy and Health Services (CPHPS) Peer Review Committee
6/2018	Ad Hoc Member, American Cancer Society Cancer Control and Prevention: Health Policy and Health Services (CPHPS) Peer Review Committee
1/2019-12/2023	Standing Member, American Cancer Society Cancer Control and Prevention: Health Policy and Health Services (CPHPS) Peer Review Committee
03/2019, 11/2019	Ad Hoc Member, NIH Fellowships: Risk, Prevention and Health Behavior
09/2022	Ad Hoc Member, NIH Study Section Health Services: Quality and Effectiveness
07/2023-present	Standing Member, NIH Study Section Health Services: Quality and Effectiveness

## **EDITORIAL RESPONSIBILITIES**

Ad hoc reviewer	Cancer Epidemiology Biomarkers and Prevention, 2009- Prevention Science, 2012- American Journal of Roentgenology, 2013- American Journal of Preventive Medicine, 2013- Journal of Comparative Effectiveness Research, 2013- Reviews on Recent Clinical Trials, 2015- Academic Radiology, 2015- Health Services Research, 2016- JAMA Oncology, 2016- Gastroenterology, 2016- Annals of Internal Medicine, 2016- BMC Cancer, 2016- Prevention Science, 2016- JAMA Internal Medicine, 2018- Cancer, 2018- The Patient – Patient Centered Outcomes Research, 2018- Journal of the American Board of Family Physicians, 2019-
-----------------	--

Annals of Surgical Oncology, 2019-  
Cancer Medicine, 2020-  
Breast Cancer Research and Treatment, 2020-  
Journal of the National Cancer Institute, 2020-  
Journal of the American College of Radiology, 2020-  
Journal of Public Health, 2020-  
Breast, 2021-  
BMC Cancer, 2021-  
BMC Women's Health, 2021  
Preventive Medicine, 2021-  
Patient Education and Counseling, 2021-  
Preventive Medicine Reports, 2022-  
Cancer Prevention Research, 2022-  
Pilot and Feasibility Studies, 2022-  
Cancer Control, 2022-  
Vaccine, 2023-  
CHEST, 2023-  
ATS, 2024-

## **RESEARCH FUNDING**

### ***Completed Research Funding (as Principal Investigator or Co-Investigator)***

Role: Research Fellow  
Title of Project: Environmental and Molecular Epidemiology Training Grant.  
Source: National Institute of Environmental Health Sciences Training Award  
Project Number: 5T32ES007262-13  
Dates of Project: 2003-2006  
Effort: 100%  
PI: Harvey Checkoway

Role: Principal Investigator  
Title of Project: Medications, multivitamins, and breast cancer survival.  
Source: Prevent Cancer Foundation Fellow (Post-doctoral Fellowship Award)  
Dates of Project: 2008-2010  
Effort: 50%  
Direct Costs: \$80,000  
Aim: *Determine association between medication use and survival in breast cancer survivors.*

Role: Scholar  
Title of Project: Comparative Effectiveness Research Scholar  
Source: Career Development Award funded by Agency for Healthcare Research and Quality  
Project Number: K12HS019482  
Dates of Project: 2010-2013

Effort: 80%  
Direct Costs: \$206,797  
PI: Sean Sullivan  
Aim: *A mentored Comparative Effectiveness Research Training Program (K12) at the University of Washington that equips Scholars with the skills to plan, conduct, and apply practical clinical and health services research.*

Role: Principal Investigator  
Title of Project: Interactive voice response and colorectal cancer screening.  
Source: Group Health Research Institute Development Fund.  
Dates of Project: 2010-2012  
Effort: 5%  
Direct Costs: \$37,882  
Aim: *To compare the effectiveness of IVR to usual care on colorectal cancer screening rates to increase adherence at 3, 6, 9 and 12 months after the intervention.*

Role: Principal Investigator  
Title of Project: Mammographic breast density and ovarian cancer.  
Source: National Cancer Institute  
Project Number: R03 CA159080  
Dates of Project: 2011-2014  
Effort: 10%  
Direct Costs: \$100,000  
Aim: *To estimate the association between mammographic breast density and incident ovarian cancer risk*

Role: Co-Investigator  
Title of Project: Risk-based cancer screening in community settings.  
Source: National Cancer Institute  
Project Number: P01CA149365  
Dates of Project: 2011-2016  
Effort: 5%  
Direct Costs: \$23,965,000  
PI: Diana Miglioretti, Karla Kerlikowske, Anna Tosteson  
Aim: *Project 3, Community-based Utilization of Breast Imaging Technologies, will assess risk-based screening in diverse populations and identify disparities in access and use of new technologies.*

Role: Project Lead (R01-size project)  
Title of Project: Studying colorectal cancer: effectiveness of screening strategies (SuCESS)  
Source: National Cancer Institute  
Project Number: U54 CA163261  
Dates of Project: 2011-2018  
Effort: 15-25%  
Direct Costs: \$4,705,276  
PI: Carolyn Rutter and Jessica Chubak  
Aim: *To generate evidence about how screening is practiced, patient decisions regarding screening modalities, and comparative effectiveness of different screening regimens as practiced.*

Role: Co-Investigator  
Title of Project: Effectiveness of pre-operative MRI in breast cancer surgery and outcomes  
Source: National Cancer Institute

Project Number: R01 CA149365  
Dates of Project: 2012-2016  
Effort: 5%  
Direct Costs: \$695,000  
PI: Tracy Onega  
Aim: *To examine the effectiveness of pre-operative breast MRI in women over age 65 in BCSC and SEER-Medicare*

Role: Principal Investigator  
Title of Project: Comparative effectiveness of surveillance imaging strategies in breast cancer  
Source: Patient Centered Outcomes Research Institute  
Project Number: CE-1304-6656  
Dates of Project: 2013-2018  
Effort: 40%  
Direct Costs: \$1,346,619  
Aim: *To compare mammography to MRI using data from the Breast Cancer Surveillance Consortium—the largest collection of breast cancer surveillance data in the nation and will use data from more than 36,000 women diagnosed with breast cancer between 2005 and 2012 to determine how well each test works.*

Role: Principal Investigator  
Title of Project: Complication rates from complex spine surgery.  
Source: Group Health Research Institute Development Fund  
Dates of Project: 2013-2014  
Effort: 10%  
Direct Costs: \$98,000  
Aim: *To evaluate 30 days and one year complication rates in complex spine patients from 2008-2012.*

Role: Project Lead  
Title of Project: Systematic Evidence Reviews to Support the U.S. Preventive Services.  
Source: Agency for Healthcare Research and Quality  
Project Number: HHS290201200015i  
Dates of Project: 2014-2016  
Effort: 20%  
Direct Costs: \$233,517  
PI: Evelyn Whitlock  
Aim: *To complete systematic evidence review for skin cancer screening for US Preventive Services Task Force*

Role: Principal Investigator  
Title of Project: Lung cancer screening registry  
Source: Group Health Research Institute Development Fund  
Dates of Project: 2015-2016  
Effort: 5%  
Direct Costs: \$60,000  
Aim: *To build Group Health infrastructure on the conduct of lung cancer screening.*

Role: Site Principal Investigator  
Title of Project: Applying breast density to risk counseling  
Source: National Cancer Institute  
Project Number: R01CA190221  
Dates of Project: 2015-2020

Effort: 15%  
Direct Costs: \$701,283  
PI: Suzanne O'Neill  
Aim: *To implement and evaluate a web-based interactive intervention vs. usual care among members of Group Health (aged 40-69) whose high breast density and other risk factors place them at high 5-year (>1.66 percent) or lifetime (>20 percent) risk for breast cancer.*

Role: Principal Investigator  
Title of Project: The Clare Project 2016  
Source: Group Health Research Institute Development Fund  
Dates of Project: 2016  
Effort: 5%  
Direct Costs: \$54,000  
Aim: *To understand patient, caregiver and provider perspectives in the clinical decision making for AYA patients with advanced cancer.*

Role: Site Principal Investigator/Primary Mentor  
Title of Project: K12 Mentor awards.  
Source: Agency for Healthcare Research and Quality  
Project Number: K12 HS022982  
Dates of Project: 2015-2016  
Effort: 2%  
Direct Costs: \$10,000  
Aim: *To support senior mentors for K12 Scholars in patient-centered outcomes research in Cohort 2.*

Role: Site Principal Investigator  
Title of Project: Patient Voices: Supporting Patient Involvement in the Learning Health Care System.  
Source: Eugene Washington Patient Engagement Award funded by Patient Centered Outcomes Research Institute.  
Dates of Project: 2015-2017  
Effort: 5%  
Direct Costs: \$16,386  
PI: Danielle Lavalley  
Aim: *To establish training, provide tools, and create a network to help researchers and patients better connect and collaborate in patient-centered outcomes research.*

Role: Site Principal Investigator/Primary Mentor  
Title of Project: K12 Mentor awards.  
Source: Agency for Healthcare Research and Quality  
Project Number: K12 HS022982  
Dates of Project: 2016-2017  
Effort: 2%  
Direct Costs: \$15,000  
Aim: *To support senior mentors for K12 Scholars in patient-centered outcomes research in Cohort 3.*

Role: Principal Investigator  
Title of Project: National trends in end-of-life care for adolescent and young adult (AYA) cancer patients  
Source: National Cancer Institute  
Project Number: R21CA205309

Dates of Project: 2016-2019  
Effort: 12%  
Direct Costs: \$160,080  
Aim: *To describe and compare the receipt of medical, surgical, and pharmacologic interventions in AYA population within the last 30 days and 365 days of life by evaluating temporal trends and U.S. geographic variation.*

Role: Site Principal Investigator  
Title of Project: Comorbidity and screening outcomes among older women undergoing mammography  
Source: National Cancer Institute  
Project Number: R01CA207361  
Dates of Project: 2016-2020  
Effort: 4%  
Direct Costs: \$545,142  
PI: Dejana Braithwaite  
Aim: *To evaluate breast cancer screening outcomes in SEER-Medicare and Breast Cancer Surveillance Consortium women.*

Role: Patient Engagement Core Lead  
Title of Project: Comparative effectiveness of breast cancer screening, diagnosis and management in community practice  
Source: Patient Centered Outcomes Research Institute  
Project Number: PCS-1504-30370  
Dates of Project: 2016-2022  
Effort: 15%  
Direct Costs: \$3,831,993  
PI: Karla Kerlikowske, Diana Miglioretti, Tracy Onega, Anna Tosteson  
Aim: *To evaluate breast imaging effectiveness by breast density to screen for breast cancer and diagnosis evaluation for newly diagnosed breast cancer.*

Role: Site Principal Investigator/Primary Mentor  
Title of Project: K12 Mentor awards.  
Source: Agency for Healthcare Research and Quality  
Project Number: K12 HS022982  
Dates of Project: 2017-2018  
Effort: 2%  
Direct Costs: \$5,000  
Aim: *To support senior mentors for K12 Scholars in PCOR*

Role: Site Principal Investigator  
Title of Project: Advanced breast imaging: trends and outcomes associated with recent breast density reporting legislation  
Source: National Cancer Institute  
Project Number: R01CA207373  
Dates of Project: 2017-2021  
Effort: 15%  
Direct Costs: \$132,397  
PI: Natasha Stout  
Aim: *To determine breast imaging changes within a natural experiment of breast density notification laws within the US using commercial claims in women <65*

Role: Site Principal Investigator/Primary Mentor  
Title of Project: The University of Washington Patient Centered Outcomes Research Partnership (PCOR) Mentor funding

Source: Agency of Healthcare Research and Quality  
Project Number: R25 HS02320  
Dates of Project: 2018-2019  
Effort: 2%  
Direct Costs: \$5,000  
Aim: *To support senior mentors for scholars in PCOR.*

Role: Principal Investigator  
Title of Project: Project CONNECT  
Source: Kaiser Permanente Washington Health Research Institute Development Fund  
Dates of Project: 2018-2019  
Effort: 5%  
Direct Costs: \$72,609  
Aim: *To describe patient, caregiver and clinician experiences with peer support in complex medical conditions.*

Role: Principal Investigator  
Title of Project: Lung Cancer Screening  
Source: Kaiser Permanente Washington Health Research Institute Development Fund  
Dates of Project: 2019  
Effort: 10%  
Direct Costs: \$85,236  
Aim: *To support patient-centered approach to lung cancer screening.*

Role: Co-Investigator  
Title of Project: Making Medical Decisions with BRCA 1/2  
Source: Kaiser Permanente Washington Health Research Institute Development Fund  
Dates of Project: 2019  
Effort: 5%  
Direct Costs: \$59,957  
PI: Marlaine Figueroa Gray  
Aim: *To understand decision-making as a result of genetic testing*

Role: Principal Investigator  
*(assumed leadership as PI at study start in Oct 2021. Original PI Michael Jackson, PhD)*  
Title of Project: Effectiveness of Respiratory Virus Vaccines against Laboratory-Confirmed Outpatient Illness  
Source: Centers for Disease Control  
Project Number: 75D30121C11909  
Dates of Project: 2021-2022  
Effort: 20%  
Direct Costs: \$750,000  
Aim: *To enroll KPWA members with acute respiratory illness to estimate influenza vaccine effectiveness.*

Role: Co-Investigator  
Title of Project: Risk-based breast cancer screening and surveillance in community practice  
Source: National Cancer Institute  
Project Number: P01CA154292  
Dates of Project: 2017-2022  
Effort: 5%  
Direct Costs: \$17,492,134  
PI: Diana Miglioretti, Karla Kerlikowske, Anna Tosteson  
Aim: *To evaluate breast cancer screening in community practice in US.*

Role: Site PI and Co-Investigator  
*(assumed leadership as PI in February 2022. Original PI Diana Buist, PhD)*  
Title of Project: Using a Mixed Methods Approach to Understand Shared Decision-Making in Lung Cancer Screening  
Source: National Cancer Institute  
Project Number: R01CA222090  
Dates of Project: 2018-2023 NCE  
Effort: 10%  
Direct Costs: \$2,200,084  
PI: Lisa Carter-Bawa  
Aim: *To complete surveys on KPWA providers regarding shared decision-making and survey patients regarding satisfaction with shared decision making*

Role: Site Principal Investigator/Primary Mentor  
Title of Project: Implementation and Effectiveness of Multicomponent Genomic Health Care Interventions for Hereditary Breast and Ovarian Cancer Prevention: A Natural Experiment in Integrated Health Systems  
Source: National Human Genome Research Institute  
Dates of Project: 2019-2022 (NCE)  
Project Number: K08 HG010488  
Effort: OSC  
Direct Costs: \$93,791  
PI: Sarah Knerr  
Aim: *To develop trainee in implementation science, genomic medicine and learning health care system.*

Role: Site Principal Investigator/Co-Investigator  
Title of Project: A Simulation Modeling Study to Support Personalized Breast Cancer Prevention and Early Detection in High-Risk Women  
Source: National Cancer Institute  
Dates of Project: 2021-2023 (NCE)  
Project Number: R03 CA259896  
Effort: 2%  
Direct costs: \$100,000  
PI: Jeanne Mandelblatt  
Aim: *To use CISNET simulation model to synthesize data on clinical risk factors and the impact of early detection with screening and primary prevention with risk-reducing medication to provide personalized data that will help identify women who are more likely to benefit from various interventions or combinations of interventions with the least harms*

Role: Pilot Principal Investigator  
Title of Project: Quality metrics in time to biopsy and lung cancer diagnosis in cancer screening population  
Source: Alliance for Clinical Trials in Oncology  
Project Number: UG1CA189823  
Dates of Project: 2021-2023  
Effort: None  
Direct Costs: \$91,250  
PI: Monica M. Bertagnolli  
Aim: *To develop benchmarking reports for positive lung cancer screening scans in NCI Community Oncology Research Program (NCORP) practices*

Role: Co-Investigator

Title of Project: Advancing Equitable Risk-Based Breast Cancer Screening and Surveillance in Community Practice  
Source: National Cancer Institute  
Project Number: P01CA154292-11  
Dates of Project: 2022-2027  
Effort: 5%  
Direct Costs: \$17,492,134  
PI: Diana L Miglioretti, Karla Kerlikowske, Anna Tosteson  
Aim: *The major goal of the program is to provide evidence to improve the equity and effectiveness of breast cancer screening and surveillance. Findings will inform public health efforts to promote equitable risk-based screening and surveillance and reduce breast cancer disparities.*

Role: Site PI  
Title of Project: Collaborative Technology Development and Analyses to Support Genetic Epidemiology in Washington State  
Source: Center for Disease Control  
Project Number: 75D30122C14368  
Dates of Project: 2022-2024  
Effort: 8%  
Direct Costs: \$110,990  
PI: Lea Starita  
Aim: *University of Washington received a contract from the CDC to study the epidemiology of respiratory viruses in the greater Seattle area at the genetic level of the virus. KPWA will be contributing to this work by providing residual specimens originally collected for the CDC's Influenza Vaccine Effectiveness Network*

Role: Site Principal Investigator/Cancer Care Delivery Research Lead  
Title of Project: Kaiser Permanente NCI National Community Oncology Research Program NCORP Renewal  
Source: National Cancer Institute  
Dates of Project: 2019-2026  
Project Number: UG1CA189821  
Effort: 8%  
Direct Costs: \$379,713  
PI: Marie Suga  
Aim: *To support and execute clinical trials and observational studies within the Kaiser Foundation NCI Community Oncology Research program.*

### **Current Research Funding (as Principal Investigator or Co-Investigator)**

Role: Project Co-Lead (R01-sized project)  
Title of Project: Clinical Care Gaps and Unmet Needs in Adolescent and Young Adult (AYA) Cancers (Project 2) (Hahn, Wernli, Chawla)  
Source: National Cancer Institute  
Dates of Project: 2020-2026  
Project Number: P01CA233432  
Effort: 6-12%  
Direct costs: \$8,901,762  
PI: Larry Kushi, Jessica Chubak, Erin Hahn, Hazel Nichols, Theresa Keegan  
Aim: *To investigate cancer care and outcomes among ~90,000 AYAs diagnosed with cancer from 2006-2021, including surveys with ~5,000 planned respondents, and*

*clinical and cancer registry data from Kaiser Permanente Northern California, Kaiser Permanente Southern California, and the States of California, North Carolina, and Utah.*

Role: Principal Investigator  
Title of Project: Multilevel Interventions to Increase Adherence to Lung Cancer Screening  
Source: National Cancer Institute  
Project Number: R01CA262015  
Dates of Project: 2021-2026  
Effort: 25%  
Direct Costs: \$2,499,253  
Aim: *To evaluate the impact of two multilevel interventions to improve adherence to lung cancer screening.*

Role: Principal Investigator  
Title of Project: Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state, 2022-2027  
Source: Centers for Disease Control  
Project Number: 1U01IP001191  
Dates of Project: 2022-2027  
Effort: 20%  
Direct Costs: \$6,109,350  
Aim: *To enroll KPWA members with acute respiratory illness to estimate influenza vaccine effectiveness.*

Role: Site PI, Co-Investigator  
Title of Project: Evaluating centralizing interventions to address low adherence to lung cancer screening follow-up in decentralized settings  
Source: National Cancer Institute  
Project Number: R01CA284032  
Dates of Project: 2023-2028  
Effort: 5%  
Direct Costs: \$451,647  
PI: Matthew Triplette  
Aim: *To generate evidence of barriers and facilitators to lung cancer screening follow-up in decentralized community programs, adapt and introduce centralizing interventions in these settings and rigorously measure the effectiveness and implementation of these interventions.*

Role: Principal Investigator  
Title of Project: Patient and provider communication in Larch Study  
Source: National Cancer Institute  
Project Number: R01CA262015 Administrative Supplement  
Dates of Project: 2023-2026  
Effort: Concurrent effort  
Direct Costs: \$99,999  
Aim: *To understand digital health interventions in lung cancer screening*

Role: Site Principal Investigator  
Title of Project: The Opioid Consortium (OPICO) to investigate the effects of using opioids on cancer risk  
Source: National Cancer Institute  
Project Number: U01CA289226  
Dates of Project: 2024-2029  
Effort: 7%

Direct Costs: \$308,493  
PI Mahdi Sheikh  
Aim: *To understand the association between opioid use and cancer incidence*

Role: Principal Investigator  
Title of Project: Quality improvement in lung cancer screening: testing innovations for anticipated HEDIS metrics  
Source: Lilly Grant Office  
Dates of Project: 2024-2026  
Effort: 10%  
Direct Costs: \$384,214  
Aim: *To test QI strategies to improve lung cancer screening*

Role: Multiple Principal Investigator (Wernli, Triplette, Escaron)  
Title of Project: Expanding lung cancer screening to achieve excellence (EXHALE)  
Source: National Cancer Institute  
Project Number: UG3CA305707  
Dates of Project: 2025-2027  
Effort: 15%  
Direct Costs: \$1,243,545  
Aim: *To improve lung cancer screening access, uptake and adherence in federally qualified health centers in US.*

## **TEACHING AND MENTORING RESPONSIBILITIES**

### ***Teaching Activities***

2003 Teaching Assistant, Introduction to Epidemiology EPI 420 course, Department of Epidemiology, University of Washington, Seattle WA

2005-2006 Teaching Assistant, Epidemiology and Biostatistics course, School of Medicine, University of Washington, Seattle WA

2008 Instructor, Epidemiology course, Seattle Midwifery School, Seattle WA

2011-2013 Guest lecturer, Graduate seminar, School of Social Work, University of Washington, Seattle WA

2014 Guest lecturer, HSERV 592K Graduate Student Seminar, Department of Health Services, University of Washington, Seattle WA. January 2014

2014 Guest lecturer, PHARM 597 Graduate Student Seminar, Department of Pharmaceutical Outcomes Research Program, University of Washington, Seattle WA. December 2014.

2015 Guest lecturer, EPI 583 Graduate Student Seminar, Department of Epidemiology, University of Washington, Seattle, WA. April 2015

2015 Guest lecturer, Epidemiology 101, Kaiser Permanente Washington Health Research Institute

2016 Preceptor, EPI 514 Applications in Epidemiologic Methods, Department of Epidemiology, University of Washington, Seattle, WA. Spring 2016

2016 Seminar speaker, University of Washington, Surgical Outcomes Research Center (SORCE) Fellows Methods seminar, Seattle, WA, December 2016

2018 Peer reviewer, Mock Study section for K12 and KL2 Scholars

- 2019 Guest lecturer, Epidemiology 101, Kaiser Permanente Washington Health Research Institute
- 2024 Guest panelist, EPI 588/HSPOP 578: Preparing, Writing, and Critiquing Research Proposals, University of Washington, May 15
- 2024 Guest lecturer, HSS300.08: Cancer Screening Research, Kaiser Permanente Bernard J. Tyson School of Medicine, October 24
- 2025 Guest lecturer, HSS300.08: Cancer Screening Research, Kaiser Permanente Bernard J. Tyson School of Medicine, October 31

## **Thesis Committees**

### **Master thesis**

Cameron Haas, 2015-2017

Member, Master of Public Health, Epidemiology, University of Washington

Title: Patterns in completion of colorectal cancer screening using fecal immunochemical tests in a health maintenance organization setting

Sharon Hwee, 2017-2018

Chair, Master of Science, Health Services, University of Washington

Title: U.S. opioid prescribing trends for adolescent and young adult cancer patients in last year of life, 2002 – 2016: A study from the Clare Project

Magali Sanchez, 2022-2023

Chair, Master of Public Health, Epidemiology, University of Washington

Title: Association of neighborhood disadvantage and COVID-19 and influenza vaccine uptake and positivity among Kaiser Permanente Washington Flu Vaccine Effectiveness subjects, 2018-2022

### **Doctoral thesis**

Cameron Haas MPH, 2017-2021

Member, PhD Committee, Epidemiology, University of Washington

Title: The genetics of sex hormones and their effects on mammographic density in women

Anjali Vasavada MPH, 2023-anticipated spring 2026

Chair, PhD Committee, Epidemiology, University of Washington

Title: Digital health technologies in lung cancer screening

Magali Sanchez MPH, 2023-anticipated spring 2026

Chair, PhD Committee, Epidemiology, University of Washington

Title: Social disadvantage and influenza vaccinations: implications for US policy

## **ADVISING & FORMAL MENTORING**

### **Early career scientists**

2014-2016 Josh Roth, PhD, Assistant Member and K12 Scholar, Fred Hutchinson Cancer Research Center, served as secondary mentor

- 2015-2016 Sara Javid, MD, Associate Professor, Department of Surgery, University of Washington, served as CRN mentor
- 2015- Marlane Figueroa Gray, PhD, Research Associate and Assistant Investigator, Kaiser Permanente Washington Health Research Institute, served as a primary mentor (to 2020) and currently a member of mentoring team
- 2016-2023 Sarah Knerr, PhD, Assistant Professor and K12 Fellow at University of Washington, served as a primary mentor on K12 and K08 awards
- 2016-2019 Zachary Marcum, PhD, Assistant Professor and K12 Scholar, University of Washington, served as a secondary mentor
- 2019- Lorella Palazzo, PhD, Collaborative Scientist, Kaiser Permanente Washington Health Research institute, serve as primary mentor

***Post-Doctoral Fellows***

- 2015-2016 Carolyn Bennette, PhD, Post-doctoral Fellow and K12 Scholar, University of Washington, served as primary mentor
- 2015-2016 Sarah Knerr, PhD, Post-doctoral Fellow at Group Health Research Institute, served as a secondary mentor

***Doctoral students***

- 2017-2021 Cameron Haas, PhD student, Department of Epidemiology, University of Washington, served as primary mentor
- 2019 Matthew Wise, Medical student, University of North Texas Health Science (UNTHSC), Texas College of Osteopathic Medicine (TCOM), served as research preceptor
- 2023- Anjali Vasavada, PhD student, Department of Epidemiology, University of Washington, dissertation chair
- 2023- Magali Sanchez, PhD student, Department of Epidemiology, University of Washington, primary mentor

***Master students***

- 2010-2012 Hannah Cohen-Cline, MPH student, served as a primary mentor
- 2015-2017 Cameron Haas, MPH Student, Department of Epidemiology, University of Washington, served as a primary mentor
- 2017-2018 Sharon Hwee, MS Student, Department of Health Services, University of Washington, served as a primary mentor
- 2022-2023 Magali Sanchez, MPH Student, Department of Epidemiology, University of Washington, served as primary mentor
- 2023-2024 James Licitra, MPH Student, Purdue University, Public Health Field Mentor

***Undergraduate students***

- 2012-2013 Danielle Olmstead, Undergraduate Group Health Student Intern, served as primary mentor

**PUBLICATIONS**

Google Scholar: h-index 43

Research Gate: h-index 39

Citations: &gt;5700

***Published manuscripts in refereed journals***

\*Primary mentor

\*\*Senior author

1. Klonoff-Cohen HS, Edelstein SL, Lefkowitz ES, Srinivasan IP, Kaegi D, Chang JC, **Wiley KJ**. The effect of passive smoking and tobacco exposure through breast milk on sudden infant death syndrome. *JAMA* 1995;273(10):795-798. PMID: 7861574
2. Machevsky AM, Patel S, **Wiley KJ**, Stephenson MA, Gondo M, Brown RS, Yi ES, Benedict WF, Anton RC, Cagle PT. Artificial neural networks and logistic regression as tools for prediction of survival in patients with Stages I and II non-small cell lung cancer. *Mod Pathol* 1998;11(7):618-625. PMID: 9688182
3. Airewele GE, Sigurdson AJ, **Wiley KJ**, Frieden BE, Calderera LW, Riccardi VM, Lewis RA, Chintagumpala MM, Ater JL, Plon SE, Bondy ML. Neoplasms in Neurofibromatosis 1 are related to gender but not to family history of cancer. *Genet Epidemiol* 2001;20(1):75-86. PMID: 11119298
4. **Wernli KJ**, Ray RM, Dao GL, Thomas DB, Checkoway H. Cancer among women textile workers in Shanghai, China: overall incidence patterns, 1989-1998. *Am J Ind Med*. 2003;44(6):595-9 PMID: 14635236
5. Camp JE, Seixas NS, **Wernli K**, Fitzgibbons D, Astrakianakis G, Thomas DB, Gao DL, Checkoway H. Development of cancer research study in Shanghai textile industry. *Int J Occup Environ Health*. 2003;9(4):347-56. PMID: 14664489
6. De Roos AJ, Ray RM, Gao DL, **Wernli KJ**, Fitzgibbons ED, Feng Z, Astrakianakis G, Thomas DB, Checkoway H. Colorectal cancer incidence among female textile workers in Shanghai, China: A case-cohort analysis of occupational exposures. *Cancer Causes Control*. 2005;16(10):1177-1188. PMID: 16215868
7. Wong E, Ray R, Gao DL, **Wernli KJ**, Li W, Fitzgibbons ED, Feng Z, Thomas DB, Checkoway H. Reproductive history, occupational exposures and thyroid cancer risk among women textile workers in Shanghai, China. *Int Arch Occup Environ Health* 2006;79(3):251-258. PMID: 16220287
8. Chang CK, Astrakianakis G, Thomas DB, Seixas DB, Ray RM, Gao DL, **Wernli KJ**, Fitzgibbons ED, Vaughan TL, Checkoway H. Occupational exposures and risks of liver cancer among Shanghai female textile workers - - A case-cohort study. *Int J Epidemiol* 2006;35(2):361-369. PMID: 16373377
9. Li W, Ray RM, Gao DL, Fitzgibbons ED, Seixas NS, Camp JE, **Wernli KJ**, Astrakianakis G, Feng Z, Thomas DB, Checkoway H. Occupational risk factors for nasopharyngeal cancer among female textile workers in Shanghai, China. *Occup Environ Med* 2006;63(1):39-44. PMC2078032
10. **Wernli KJ**, Fitzgibbons ED, Ray RM, Gao DL, Li W, Seixas N, Camp JE, Astrakianakis G, Feng Z, Thomas DB, Checkoway H. Occupational risk factors for esophageal and stomach cancers among female textile workers in Shanghai, China. *Am J Epidemiol* 2006;163(8):717-725. PMID: 16467414
11. Gold L, De Roos AJ, Ray RM, **Wernli KJ**, Fitzgibbons ED, Gao DL, Astrakianakis G, Thomas DB, Feng Z, Checkoway H. Brain tumors and occupational exposures in a cohort of female textile workers in Shanghai, China. *Scand J Work Environ Health* 2006;32(3):178-184. PMID: 16804619
12. Chang CK, Astrakianakis G, Thomas DB, Seixas NS, Camp JE, Ray RM, Gao DL, **Wernli KJ**, Li W, Fitzgibbons ED, Vaughan T, Checkoway H. Risks of biliary tract cancer and occupational exposures among Shanghai women textile workers: a case-cohort study. *Am J Ind Med* 2006;49(8):690-698. PMID: 16830349

13. **Wernli KJ**, Ray RM, Gao DL, De Roos AJ, Checkoway H, Thomas DB. Menstrual and reproductive factors in relation to risk of endometrial cancer in Chinese women. *Cancer Causes Control* 2006;17(7):949-955. PMID: 16841262
14. **Wernli KJ**, Astrakianakis G, Camp J, Ray RM, Chang CK, Li GD, Thomas DB, Checkoway H, Seixas N. Development of a job exposure matrix (JEM) for the textile industry in Shanghai, China. *J Occup Environ Hyg* 2006;3(10):521-529. PMID: 16908453
15. Li W, Ray RM, Gao DL, Fitzgibbons ED, Seixas NS, Camp JE, **Wernli KJ**, Astrakianakis G, Feng Z, Thomas DB, Checkoway H. Occupational risk factors for pancreatic cancer among female textile workers in Shanghai, China. *Occup Environ Med* 2006;63(12):788-93. PMC2078009.
16. Rosenblatt KR, Gao DL, Ray RM, Rowland MR, Nelson ZC, **Wernli KJ**, Li W, Thomas DB. Induced abortions and the risk of all cancers combined and site-specific cancers in Shanghai. *Cancer Causes Control* 2006;17(10):1275-1280. PMID: 17111259
17. Astrakianakis G, Seixas NS, Ray R, Camp JE, Gao DL, Feng Z, Li W, **Wernli KJ**, Fitzgibbons ED, Thomas DB, Checkoway H. Lung cancer risks among female textile workers exposed to endotoxin. *J Natl Cancer Inst* 2007;99(5):357-64. PMID: 17341727
18. Ray RM, Gao DL, Li W, **Wernli KJ**, Astrakianakis G, Seixas NS, Camp JE, Fitzgibbons ED, Feng Z, Thomas DB, Checkoway H. Occupational exposures and breast cancer among women textile workers in Shanghai. *Epidemiology* 2007;18(3):383-392. PMID: 17435449
19. Rosenblatt KR, Gao DL, Ray RM, Nelson ZC, **Wernli KJ**, Li W, Thomas DB. Monthly injectable contraceptives and risk of all cancer combined and site-specific cancers in Shanghai. *Contraception* 2007;76(1):40-44. PMID: 17586135
20. **Wernli KJ**, Ray RM, Gao DL, Fitzgibbons ED, Camp JE, Astrakianakis G, Seixas N, Wong EY, Li W, De Roos AJ, Feng Z, Thomas DB, Checkoway H. Occupational exposures and ovarian cancer in textile workers. *Epidemiology* 2008;19(2):244-250. PMID: 18300714
21. **Wernli KJ**, Newcomb PA, Hampton J, Trentham-Dietz A, Egan KM. Hormone therapy and ovarian cancer: incidence and survival. *Cancer Causes Control* 2008;19(6):605-613. PMC2729759.
22. **Wernli KJ**, Newcomb PA, Hampton J, Trentham-Dietz A, Egan KM. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. *Br J Cancer* 2008;98(11):1781-1783. PMC2410126.
23. **Wernli KJ**, Ray RM, Gao DL, Fitzgibbons ED, Camp JE, Astrakianakis G, Seixas N, Li W, De Roos AJ, Feng Z, Thomas DB, Checkoway H. Occupational risk factors for endometrial cancer among women textile workers in Shanghai, China. *Am J Ind Med* 2008;51(9):673-679. PMC2574926.
24. Rosenblatt KR, Gao DL, Ray RM, Nelson ZC, **Wernli KJ**, Li W, Thomas DB. Oral contraceptives and the risk of all cancers combined and site-specific cancers in Shanghai. *Cancer Causes Control* 2009;20(1):27-34. PMC2628413.
25. Wong EY, Ray RM, Gao DL, **Wernli KJ**, Li W, Fitzgibbons ED, Camp JE, Astrakianakis G, Seixas N, Heagerty P, Thomas DB, Checkoway H. Dust and chemical exposures, miscarriage risk among textile workers in Shanghai, China. *Occup Environ Med* 2009;66(3):161-168. PMC2862777.
26. **Wernli KJ**, Hampton JM, Trentham-Dietz A, Newcomb PA. Antidepressant medication use and breast cancer risk. *Pharmacoepidemiol Drug Saf* 2009;18(4):284-290. PMC2720762.
27. Shadman M, Newcomb PA, Hampton JM, **Wernli KJ**, Trentham-Dietz A. Non-steroidal anti-inflammatory drugs and statins in relation to colorectal cancer risk. *World J Gastroenterol* 2009;15(9):2336-2339. PMC2684598.
28. **Wernli KJ**, Wang Y, Zheng Y, Potter JD, Newcomb PA. The relationship between gravidity and parity and colorectal cancer risk. *J Women's Health* 2009; 18(7):995-1001. PMC2851134.

29. Wong EY, Ray RM, Gao DL, **Wernli KJ**, Li W, Fitzgibbons ED, Camp JE, Heagerty P, De Roos AJ, Holt VL, Thomas DB, Checkoway H. Physical activity, physical exertion, and miscarriage risk in women textile workers in Shanghai, China. *Am J Ind Med* 2010;53(5):497-505. PMC2863132.
30. **Wernli KJ**, Newcomb PA, Wang Y, Makar KW, Shadman M, Chia VM, Burnett-Hartman A, Wurscher MA, Zheng Y, Mandelson MT. Body size, IGF and growth hormone polymorphisms, and colorectal adenomas and hyperplastic polyps. *Growth Horm IGF Res* 2010;20(4):305-309. PMC2918710.
31. **Wernli KJ**, Hampton JM, Trentham-Dietz A, Newcomb PA. Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. *Pharmacoepidemiol Drug Saf* 2011;29(2):131-137. PMC3074001.
32. Checkoway H, Ray RM, Lundin JI, Astrakianakis G, Seixas NS, Camp JE, **Wernli KJ**, Fitzgibbons ED, Li W, Feng Z, Gao DL, Thomas DB. Lung cancer and occupational exposures other than cotton dust and endotoxin among women textile workers in Shanghai, China. *Occup Environ Med* 2011;68(6):425-429. PMC3071898.
33. **Wernli KJ**, Bowles EJ, Haneuse S, Elmore JG, Buist DSM. Timing of follow-up after abnormal screening and diagnostic mammograms. *Am J Managed Care* 2011;17(2):162-167. PMC3151253.
34. Coghill AE, Newcomb PA, Chia VM, Zheng Y, **Wernli KJ**, Passarelli MN, Potter JD. Pre-diagnostic NSAID use but not hormone therapy is associated with improved colorectal cancer survival in women. *Br J Cancer* 2011;104(6):763-768. PMC3048198.
35. Burnett-Hartman AN, Newcomb PA, Mandelson MT, Adams SV, **Wernli KJ**, Shadman M, Wurscher M, Makar K. Colorectal polyp type and the association with charred meat consumption, smoking and microsomal epoxide hydrolase polymorphisms. *Nutr Cancer* 2011;63(4):583-592. PMC3145495.
36. Schur E, Elmore J, Onega T, **Wernli KJ**, Sickles E, Haneuse S. The impact of obesity on follow-up after an abnormal screening mammogram. *Cancer Epidemiol Biomarkers Prev* 2012;21(2):327-336. PMC3275693.
37. Passarelli MN, Phipps AI, Potter JD, Makar KW, Coghill AE, **Wernli KJ**, White E, Chan AT, Hutter CM, Petters U, Newcomb PA. Common single-nucleotide polymorphisms in the estrogen receptor  $\beta$  promoter are associated with colorectal cancer survival in postmenopausal women. *Cancer Res* 2013;73(2):767-775. PMC3588850.
38. Braithwaite D, Zhu W, Hubbard RA, O'Meara ES, Miglioretti DL, Geller B, Dittus K, Moore D, **Wernli KJ**, Mandelblatt J, Kerlikowske K, Breast Cancer Surveillance Consortium. Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age or comorbidity score affect tumor characteristics or false positive rates? *J Natl Cancer Inst* 2013;105(5):334-341. PMC3589257.
39. **Wernli KJ**, Rutter CM, Dachmann A, Zafar H. Suspected extracolonic neoplasms detected on CT colonography: Literature review and possible outcomes. *Acad Radiol.* 2013; 20(6):667-674. PMC3654044.
40. Kerlikowske K, Zhu WW, Hubbard R, Gellar B, Dittus K, Braithwaite D, **Wernli KJ**, Miglioretti D, O'Meara ES. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. *JAMA Intern Med* 2013;173(9):807-816. PMC3699693.
41. **Wernli KJ**, Kitahara CM, Tamers SL, Al-Temimi MH, Braithwaite D. Undertaking cancer research in international settings: report from the American Society for Preventive Oncology special interest group on international issues in cancer. *Cancer Epidemiol Biomarkers Prev* 2013;22(9):1638-1641. PMC3919027.
42. Li W, Ray RM, Thomas DB, Yost MY, Davis S, Breslow N, Gao DL, Fitzgibbons ED, Camp JE, Wong EY, **Wernli KJ**, Checkoway H. Occupational exposure to magnetic fields and breast cancer among women textile workers in Shanghai, China. *Am J Epidemiol* 2013;178(7):1038-1045. PMC3783098.
43. O'Meara ES, Zhu W, Hubbard R, Braithwaite D, Kerlikowske K, Dittus K, Geller B, **Wernli KJ**, Miglioretti M. Mammographic screening interval in relation to tumor characteristics and false-positive risk by race/ethnicity and age. *Cancer* 2013;119(22):3959-3967. PMC3935985.

44. **Wernli KJ**, DeMartini WB, Ichikawa L, Lehman C, Onega TL, Kerlikowske K, Henderson L, Gellar BM, Hofmann M, Yankaskas BC, Breast Cancer Surveillance Consortium. Patterns of breast magnetic resonance imaging use in community practice. *JAMA Intern Med* 2014;174(1):125-132. PMC3905972
45. **Wernli KJ**, O'Meara E, Kerlikowske K, Miglioretti D, Muller CY, Onega T, Sprague B, Henderson L, Buist DSM. Investigation of mammographic breast density as a risk factor for ovarian cancer. *J Natl Cancer Inst* 2014;106(1):djt341. PMC3906993.
46. \*Cohen-Cline H, **Wernli KJ**, Bradford SC, Boles-Hall M, Grossman D. Use of interactive voice response and colorectal cancer screening. *Med Care* 2014;52(6):496-499.
47. Aiello Bowles EJ, **Wernli KJ**, Gray HJ, Bogart A, Delate T, O'Keefe-Rosetti M, Nekhlyudov L, Trice Loggers E. Diffusion of intraperitoneal chemotherapy in women with advanced ovarian cancer in community settings 2003-2008: The effect of the NCI clinical recommendation. *Front Oncol* 2014 10;4:43. PMC3948091.
48. \*\*Johnson K, Kamineni A, Fuller S, Olmstead D, **Wernli KJ**. How the provenance of electronic health record data matters for research: a case example using system mapping. *EGEMS (Wash DC)* 2014;2(1)1058. PMC4371416
49. **Wernli KJ**, Hubbard R, Johnson E, Chubak J, Kamineni A, Rutter CM. Patterns of colorectal cancer screening uptake in newly-eligible men and women. *Cancer Epidemiol Biomarkers Prev* 2014;23(7):1230-1237. PMC4082473.
50. Tiro JA, Kamineni A, Levin TR, Zheng Y, Schottinger JE, Rutter CM, Corley D, Skinner CS, Chubak J, Doubeni C, Halm EA, Gupta S, **Wernli KJ**, Klabunde CN. The colorectal cancer screening process in community settings: A conceptual model for the population-based research optimizing screening through personalized regimens consortium. *Cancer Epidemiol Biomarkers Prev* 2014;23(7):1147-1158. PMC4148641.
51. Lee CI, Ichikawa L, Rochelle MC, Kerlikowske K, Miglioretti DL, Sprague BL, DeMartini WB, **Wernli KJ**, Joe BN, Yankaskas BC, Lehman CD. Breast MRI BI-RADS assessments and abnormal interpretation rates by clinical indication in US community practices. *Acad Radiol* 2014 Nov;21(11):1370-6. PMC4194166.
52. Onega T, Weiss JL, Kerlikowske K, **Wernli K**, Buist DSM, Henderson LM, Goodrich ME, Alford-Teaster JA, Virnig B, Tosteson AN, DeMartini W, Hubbard R. The influence of race/ethnicity and place of service on breast reconstruction for Medicare beneficiaries with mastectomy. *Springerplus*. 2014 Aug 8;3:416. PMC4137047.
53. Li W, Ray RM, Thomas DB, Davis S, Yost M, Breslow N, Gao DL, Fitzgibbons ED, Camp JE, Wong E, **Wernli KJ**, Checkoway H. Shift work and breast cancer among women textile workers in Shanghai, China. *Cancer Causes Control* 2015;26(1):143-150. PMC4323154.
54. Gallagher LG, Li W, Ray RM, Romano ME, **Wernli KJ**, Gao DL, Thomas DB, Checkoway H. Occupational exposures and risk of stomach and esophageal cancers: Update of a cohort of female textile workers in Shanghai, China. *Am J Ind Med* 2015;58(3):267-275.
55. Kerlikowske K, Zhu W, Tosteson AN, Sprague BL, Tice JA, Lehman CD, Miglioretti DL, Breast Cancer Surveillance Consortium. Identifying women with dense breasts at high risk for interval cancer: A cohort study. *Ann Intern Med* 2015;162(10):673-681. PMC4443857.
56. Wieneke AE, Bowles EJA, Cronkite D, **Wernli KJ**, Gao H, Carrell D, Buist DSM. Validation of natural language processing to extract breast cancer pathology procedures and results. *J Pathol Inform* 2015; 6:38. PMC4485196.
57. Henderson LM, Miglioretti DL, Kerlikowske K, **Wernli KJ**, Sprague BL, Lehman CM. Breast cancer characteristics associated with digital versus film-screen mammography for screen-detected and interval cancers. *AJR Am J Roentgenol* 2015;205(3):676-684. PMC4547477.

58. Lee AY, Ichikawa L, Lee JM, Lee CI, DeMartini WB, Joe BN, **Wernli KJ**, Sprague BL, Herschorn SD, Lehman CD. Concordance of BI-RADS assessments and management recommendations for breast MRI in community practice. *AJR Am J Roentgenol* 2016;206(1):211-216. PMC4864981.
59. Miglioretti DL, Zhu W, Kerlikowske K, Sprague BL, Onega T, Buist DS, Henderson LM, Smith RA, Breast Cancer Surveillance Consortium. Breast tumor prognostic characteristics and biennial vs annual mammography, age, and menopausal status. *JAMA Oncol* 2015;1(8):1069-77. PMC4644100.
60. Haas JS, Hill D, Wellman R, Hubbard RA, Lee CI, **Wernli KJ**, Stout N, Tosteson A, Henderson LM, Alford-Teaster J, Onega T. Disparities in the use of screening magnetic resonance imaging of the breast in community practice by race, ethnicity, and socioeconomic status. *Cancer* 2016;122(4):611-617. PMC4742376.
61. \*Johnson D, Bush M, Brandzel S, **Wernli KJ**. The patient voice in research-evolution of a role. *Res Involv Engage* 2016;2:6. PMC5611646.
62. Onega T, Tosteson ANA, Weiss JA, Alford-Teaster J, Hubbard RA, Henderson LM, Kerlikowske K, Goodrich ME, Donoghue C, **Wernli KJ**, DeMartini WB, Virnig BA. Costs of diagnostic and preoperative workup with and without breast MRI in older women with a breast cancer diagnosis. *BMC Health Serv Res* 2016;16:76. PMC4769533.
63. **Wernli KJ**, Brenner AT, Rutter C, Inadomi J. Risks associated with anesthesia services during colonoscopy. *Gastroenterology* 2016;150(4):888-894. PMC4887133
64. Onega T, Weiss JE, Buist DS, Tosteson AN, Henderson LM, Kerlikowske K, Goodrich ME, O'Donoghue C, **Wernli KJ**, DeMartini WB, Virnig BA, Bennette CS, Hubbard RA. Breast MRI in the diagnostic and preoperative workup among Medicare beneficiaries with breast cancer. *Med Care* 2016;54(7):719-724. PMC5001851.
65. Hubbard RA, O'Meara ES, Henderson LM, Hill D, Braithwaite D, Haas JS, Lee CI, Sprague BL, Alford-Teaster J, Tosteson A, **Wernli KJ**, Onega T. Multilevel factors associated with long-term adherence to screening mammography in older women in the US. *Prev Med* 2016;89:169-177. PMC4969188.
66. **Wernli KJ**, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Blasi PR. Screening for skin cancer in adults: Updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA* 2016;316(4):436-447.
67. Shortreed SM, Johnson E, Rutter CM, Kamineni A, **Wernli KJ**, Chubak J. Cohort restriction based on prior enrollment: Examining potential biases in estimating cancer and mortality risk. *Obs Stud* 2016;2:51-64. PMC5435370.
68. \*\*Brandzel S, Rosenberg DE, Johnson D, Bush M, Kerlikowske K, Onega t, Henderson L, Nekhlyudov L, DeMartini W, **Wernli KJ**. Women's experiences and preferences regarding breast imaging after completing breast cancer treatment. *Patient Prefer Adherence* 2017;11:199–204. PMC5295805.
69. Carter-Harris L, Brandzel S, **Wernli KJ**, Roth J, Buist D. A qualitative study exploring why individuals opt out of lung cancer screening. *Fam Pract* 2017;34(2):239-244. PMC6279209.
70. **Wernli KJ**, Arao RF, Hubbard RA, Sprague B, Alford-Teaster J, Haas J, Henderson L, Hill D, Lee C, Tosteson A, Onega T. Change in breast cancer screening intervals since the 2009 USPSTF guideline update. *J Womens Health*, 2017;26(8):820-827. PMC5576213.
71. \*Knerr S, **Wernli KJ**, Leppig K, Ehrlich K, Graham AL, Farrell D, Evans C, Luta G, Schwartz MD, O'Neill SC. A web-based personalized risk communication and decision-making tool for women with dense breasts: Design and methods of a randomized controlled trial within an integrated health care system. *Contemp Clin Trials* 2017;56:25-33. PMC5473364.
72. Balasubramanian BA, Garcia MP, Corley DA, Doubeni CA, Haas JS, Kamineni A, Quinn VP, **Wernli K**, Zheng Y, Skinner CS. Racial/ethnic differences in obesity and comorbidities between safety-net- and non-safety-net integrated health systems. *Medicine (Baltimore)* 2017;96(11):e6326. PMC5369907.

73. \*\*Sethi RK, Buchlak QD, Yanamadala V, Anderson ML, Baldwin EA, Mecklenburg RS, Leveque JC, Edwards AM, Shea M, Ross L, **Wernli KJ**. A systematic multidisciplinary initiative for reducing the risk of complications in adult scoliosis surgery. *J Neurosurg Spine* 2017;26(6):744-750.
74. Lee JM, Ichikawa L, Valencia E, Miglioretti DL, **Wernli K**, Buist DSM, Kerlikowske K, Henderson LM, Sprague BL, Onega T, Rauscher GH, Lehman CD. Performance benchmarks for screening breast MRI in community practice. *Radiology* 2017;285(1):44-52. PMC5621720.
75. Hubbard RA, Johnson E, Chubak J, **Wernli KJ**, Kamineni A, Bogart A, Rutter C. Estimating screening test effectiveness when screening indication is unknown using generalized linear finite mixture models. *Health Serv Outcomes Res Methodol* 2017;17(2):101-112. PMC5608281.
76. Sakoda LC, Henderson LM, Caverly TJ, **Wernli KJ**, Katki HA. Applying risk prediction models to optimize lung cancer screening: Current knowledge, challenges, and future directions. *Curr Epidemiol Rep* 2017;4(4):307-320. PMC5844483.
77. Hill DA, Haas JS, Wellman R, Hubbard RA, Lee CI, Alford-Teaster J, **Wernli KJ**, Henderson LM, Stout N, Tosteson ANA, Kerlikowske K, Onega T. Utilization of breast cancer screening with magnetic resonance imaging in community practice. *J Gen Intern Med* 2018;33(3):275-283. PMC5834962.
78. Onega T, Weiss JE, Goodrich ME, Zhu W, DeMartini WB, Kerlikowske K, Ozanne E, Tosteson ANA, Henderson LM, Buist DSM, **Wernli KJ**, Herschorn SD, Hotaling E, O'Donoghue C, Hubbard R. Relationship between preoperative breast MRI and surgical treatment of non-metastatic breast cancer. *J Surg Oncol* 2017;116(8):1008-1015. PMC5760434.
79. Miles R, Wan F, Onega TL, Lenderink-Carpenter A, O'Meara ES, Zhu W, Henderson LM, Haas JS, Hill DA, Tosteson ANA, **Wernli KJ**, Alford-Teaster J, Lee JM, Lehman CD, Lee CI. Availability of supplemental magnetic resonance imaging screening among patients at elevated breast cancer risk. *J Womens Health* 2018; 27(6):748-754. PMC6007803.
80. Buist DB, Abraham L, Lee CI, Lee JM, Lehman C, O'Meara ES, Stout NK, Henderson LM, Hill D, **Wernli KJ**, Haas JS, Tosteson ANA, Kerlikowske K, Onega T. Breast biopsy intensity and findings following breast cancer screening in women with and without a personal history of breast cancer. *JAMA Intern Med* 2018;178(4):458-468. PMC5876894.
81. Henderson LM, Hubbard RA, Zhu W, Weiss J, **Wernli KJ**, Goodrich ME, Kerlikowske K, DeMartini W, Ozanne E, Onega TL. Preoperative breast magnetic resonance imaging use by breast density and family history of breast cancer. *J Womens Health* 2018; 27(8):987-993. PMC6104247.
82. Singal AG, Corley DA, Kamineni A, Garcia M, Zheng Y, Doria-Rose PV, Quinn VP, Jensen CD, Chubak J, Tiro J, Doubeni CA, Ghai NR, Skinner CS, **Wernli K**, Halm EA. Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States. *Am J Gastroenterol* 2018;113(5):746-754. PMC6476786.
83. Onega T, Zhu W, Weiss JE, Goodrich M, Tosteson ANA, DeMartini W, Virnig BA, Henderson LM, Buist DSM, **Wernli KJ**, Kerlikowske K, Hubbard RA. Preoperative breast MRI and mortality in older women with breast cancer. *Breast Cancer Res Treat* 2018;170(1):149-157. PMC5994182.
84. \*\*Greene SM, Brandzel S, **Wernli KJ**. From Principles to Practice: Real-World Patient and Stakeholder Engagement in Breast Cancer Research. *Perm J* 2018;22:17-232. PMC6004970.
85. \*Roth JA, Carter-Harris L, Brandzel S, Buist D, **Wernli KJ**. A qualitative study exploring patient motivations for screening for lung cancer. *PLoS One* 2018;13(7):e0196758. PMC6033377.
86. \*Gray MF, Ludman EJ, Beatty T, Rosenberg AR, **Wernli KJ**. Balancing hope and risk among adolescent and young adult cancer patients with late-stage cancer: A qualitative interview study. *J Adolesc Young Adult Oncol* 2018 7(6):673-680. PMC6909757.
87. Lee CI, Zhu W, Onega T, Germino J, O'Meara ES, Lehman C, Henderson LM, Haas JS, Kerlikowske K, Sprague BL, Rauscher GH, Tosteson ANA, Alford-Teaster J, **Wernli KJ**, Miglioretti DL. The effect of digital breast tomosynthesis adoption on facility-level breast cancer screening volume. *AJR Am J Roentgenol* 2018;211(5):957-963. PMC6438161.

88. Chubak J, McLerran D, Zheng Y, Singal AG, Corley DA, Doria-Rose VP, Doubeni CA, Kamineni A, Haas JS, Halm EA, Skinner CS, Zauber ZG, **Wernli KJ**, Beaber EF, PROSPR Consortium. Receipt of colonoscopy following diagnosis of advanced adenomas: An analysis within integrated healthcare delivery systems. *Cancer Epidemiol Biomarkers Prev* 2019;28(1):91-98. PMC6324953.
89. Beaber EF, Sprague BL, Tosteson ANA, Haas JS, Onega T, Schapira MM, McCarthy AM, Li CI, Herschorn SD, Lehman CD, **Wernli KJ**, Barlow WE. Multilevel predictors of continued adherence to breast cancer screening among women ages 50-74 years in a screening population. *J Women's Health* 2019; 28(8):1051-1059. PMC6703243.
90. Arasu VA, Miglioretti DL, Sprague BL, Alsheik NH, Buist DSM, Henderson LM, Herschorn SD, Lee JM, Onega T, Rauscher GH, **Wernli KJ**, Lehman CD, Kerlikowske K. Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk. *J Clin Oncol* 2019; 20;37(12):954-963. PMC6494266.
91. \*Knerr S, Bowles EJ, Leppig KA, Buist DS, Gao H, **Wernli KJ**. Trends in BRCA test utilization in an integrated health system, 2005-2015. *J Nat Cancer Inst* 2019 Aug 1;111(8):795-802. PMC6695306.
92. \*Haas C, Phipps A, Hajat A, Chubak J, **Wernli KJ**. Time to fecal immunochemical test completion for colorectal cancer screening. *Am J Manag Care*. 2019;25(4):294-300. PMC7170013.
93. Breen N, Skinner CS, Zheng Y, Inrig S, Corley DA, Beaber EF, Garcia MP, Chubak J, Doubeni C, Quinn V, Haas JS, Li C, **Wernli KJ**, Klabunde CN. Time to follow-up after colorectal cancer screening by health insurance type. *Am J Prev Med* 2019; 56(5):e143-e152. PMC6820676
94. **Wernli KJ**, Ichikawa L, Kerlikowske K, Buist DSM, Brandzel SD, Bush M, Johnson D, Henderson LM, Nekhlyudov L, Onega T, Sprague B, Lee J, Lehman C, Miglioretti D. Surveillance breast MRI and mammography: comparison in women with a personal history of breast cancer. *Radiology* 2019; 292(2):311-318. PMC6694722.
95. Kerlikowske K, Sprague BL, Tosteson ANA, **Wernli KJ**, Rauscher GH, Johnson D, Buist DSM, Onega T, Henderson LM, O'Meara ES, Miglioretti DL. Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging. *JAMA Intern Med* 2019;179(9):1230-1239. PMC6604099.
96. \*\*Henderson LM, Ichikawa L, Buist DSM, Lee J, Bush M, Johnson D, Onega T, Nekhlyudov L, Kerlikowske K, Miglioretti DL, Sprague BL, **Wernli KJ**. Patterns of breast imaging use among women with a personal history of breast cancer. *J Gen Intern Med* 2019;34(10):2098-2106. PMC6816668.
97. \*\*Schifferdecker KE, Tosteson ANA, Kaplan C, Kerlikowske K, Buist DSM, Henderson LM, Johnson D, Jaworski J, Jackson-Nefertiti G, Ehrlich K, Marsh MW, Vu L, Onega T, **Wernli KJ**. Knowledge and perception of breast density, screening mammography, and supplemental screening: In search of "informed." *J Gen Intern Med* 2020;35(6):1654-1660. PMC7280373.
98. Mahorter SS, Knerr S, Bowles EJA, **Wernli KJ**, Gao H, Schwartz MD, O'Neill SC. Prior breast density awareness, knowledge, and communication in a health-system embedded behavioral intervention trial. *Cancer* 2020;126(8):1614-1621. PMC7103492.
99. Buist DSM, Ichikawa L, **Wernli KJ**, Lee CI, Henderson LM, Kerlikowske K, Bowles EJA, Miglioretti DL, Specht J, Rauscher G, Sprague B, Onega T, Lee J. Facility variability in examination indication among women with prior breast cancer: Implications and the need for standardization. *J Am Coll Radiol* 2020;17(6):755-764. PMC7275918.
100. Warner ET, Kennedy M, Maschke A, Hopkins MF, **Wernli KJ**, Gunn CM. Evaluation of existing patient educational materials and development of a brochure for women with dense breasts. *Breast* 2020;50:81-84. PMC7110420.
101. \*Haas CB, Nekhlyudov L, Lee J, Javid S, Bush M, Johnson D, Gleason T, Kaufman C, Specht J, Stitham S, **Wernli KJ**. Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review and meta-analysis. *Breast Cancer Res Treat* 2020;181(2):255-268. PMC7262783.

102. **Wernli KJ**, Callaway KA, Henderson LM, Kerlikowske K, Lee JM, Ross-Degnan D, Wallace JK, Wharam JF, Zhang F, Stout NK. Trends in Screening Breast Magnetic Resonance Imaging Use among US Women, 2006 to 2016. *Cancer* 2020;126(24):5293-5302. PMC8568334.
103. **Wernli KJ**, Bowles EA, Knerr S, Leppig KA, Ehrlich K, Gao H, Schwartz MD, O'Neill SC. Characteristics associated with participation in ENGAGED 2 – a web-based breast cancer risk communication and decision support trial. *Perm J* 2020;24:1-4. PMC7849258.
104. **Wernli KJ**, Knerr S, Li T, Leppig K, Ehrlich K, Farrell D, Gao H, Bowles EJA, Graham AL, Luta G, Jayasekera J, Mandelblatt JS, Schwartz MD, O'Neill SC. Effect of personalized breast cancer risk tool on chemoprevention and breast imaging: ENGAGED 2 trial. *JNCI Cancer Spectrum* 2021;5(1):pkaa114. PMC7853161.
105. Miglioretti DL, Bissell MCS, Kerlikowske K, Buist DSM, Cummings SR, Henderson LM, Onega T, O'Meara ES, Rauscher GH, Sprague BL, Tosteson ANA, **Wernli KJ**, Lee JM, Lee CI. Assessment of a risk-based approach for triaging mammography examinations during periods of reduced capacity. *JAMA Network Open*, 2021;4(3):e211974. PMC7994953.
106. Lee JM, Ichikawa L, **Wernli KJ**, Bowles EJA, Specht J, Kerlikowske K, Miglioretti D, Lowry K, Tosteson, ANA, Stout NK, Houssami N, Onega T, Buist DSM. Digital mammography performance and outcomes in women with a personal history of breast cancer, 2007-2016. *Radiology*. 2021 Aug;300(2):290-300. PMC8328154
107. Zhang D, Abraham L, Demb J, Miglioretti DL, Advani S, Sprague BL, Henderson LM, Onega T, **Wernli KJ**, Walter LC, Kerlikowske K, Schousboe JT, O'Meara ES, Braithwaite D. Function-related indicator and outcomes of screening mammography in older women: evidence from the Breast Cancer Surveillance Consortium-Medicare Population. *Cancer Epidem Biomark Prev* 2021 Aug;30(8):1582-1590. PMC8563300.
108. Schifferdecker KE, Vaclavik D, **Wernli KJ**, Buist DSM, Kerlikowske K, Sprague BL, Henderson LM, Johnson D, Budesky J, Jackson-Nefertiti G, Miglioretti D, Tosteson ANA. Women's considerations and experiences for breast cancer screening and surveillance during the COVID-19 pandemic in the United States: A focus group study. *Preventive Medicine* 2021 Oct;151:106542. PMC8721569.
109. **Wernli KJ**, Tuzzio L, Brush SA, Ehrlich K, Gao H, Anderson M, Palazzo L. Understanding patient and clinical stakeholder perspectives to improve lung cancer screening. *Perm J* 2021;25:20.295. PMC8817936.
110. \*\*Bowles EJA, O'Neill SC, Li T, Knerr S, Mandelblatt JS, Schwartz MD, Jayasekera J, Leppig K, Ehrlich K, Farrell D, Gao H, Graham AL, Luta G, **Wernli KJ**. Effect of a randomized trial of a web-based intervention on patient-provider communication about breast density. *J of Women's Health* 2021 Nov;30(11):1529-1537. PMC8823670.
111. Kerlavage AR, Kirchoff AC, Guidry Auvil JM, Sharpless NE, Davis KL, Reilly K, Reaman G, Penberthy L, Deapen D, Hwang A, Durbin E, Gallotto S, Aplenc R, Volchenboum S, Heath A, Aronow B, Zhang J, Vaske O, Alonzo T, Nathan P, Poynter J, Armstrong G, Hahn E, **Wernli KJ**, Greene C, DiGiovanna J, Resnick A, Shalley E, Nadaf S, Kibbe W. Cancer Informatics for Cancer Centers: Scientific Drivers for Informatics, Data Science, and Care in Pediatric, Adolescent, and Young Adult Cancer. *J Clin Oncol Clinical Cancer Informatics* 2021 Aug;5:881-896. PMC8763339.
112. Lowry KP, Bissell MCS, Miglioretti DL, Kerlikowske K, Alsheik N, Macarol T, Bowles EJA, Buist DSM, Tosteson ANA, Henderson L, Herschorn SD, **Wernli KJ**, Weaver DL, Stout NK, Sprague BL. Breast Biopsy Recommendations and Breast Cancers Diagnosed during the COVID-19 Pandemic. *Radiology*. 2022 May;303(2):287-294. PMC8544262.
113. Smith RE, Sprague B, Henderson LM, Kerlikowske K, Miglioretti DL, Buist DSM, **Wernli KJ**, Onega T, Schifferdecker K, Jackson-Nefertiti G, Johnson D, Budesky J, Tosteson ANA. Breast Density Knowledge in a Screening Mammography Population Exposed to Density Notification. *J Am Coll Radiol*. 2022 May;19(5):615-624. PMC9119699.

114. **Wernli KJ**, Smith RE, Henderson LM, Zhao W, Durham DD, Schifferdecker K, Kaplan C, Buist DSM, Kerlikowske K, Miglioretti DL, Onega T, Alsheik NH, Sprague BL, Jackson-Nefertiti G, Budesky J, Johnson D, Tosteson ANA. Decision quality and regret with treatment decisions in women with breast cancer: Pre-operative breast MRI and breast density. *Breast Cancer Res Treat.* 2022 Aug;194(3):607-616. PMC9642106.
115. Lowry KP, Callaway KC, Lee JM, Zhang F, Ross-Degnan D, Wharam JF, Kerlikowske K, **Wernli KJ**, Kurian AW, Henderson LM, Stout NK. Trends in Annual Surveillance Mammography Participation Among Breast Cancer Survivors from 2004 to 2016. *J Natl Compr Canc Netw* 2022;20(4):379-386. PMID: 35390766.
116. Onega T, Zhu W, Kerlikowske K, Miglioretti DL, Lee CI, Henderson LM, Tosteson ANA, **Wernli KJ**, diFlorio R, Weaver DL, Buist DSM. Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield. *Breast Cancer Res Treat.* 2022 Jan;191(1):177-190. PMID: 34686934.
117. Zhang D, Abraham L, Sprague BL, Onega T, Advani S, Demb J, Miglioretti DL, Henderson LM, **Wernli KJ**, Walter LC, Kerlikowske K, Schousboe JT, Chrischilles E, Braithwaite D, O'Meara. Mammography adherence in relation to function-related indicators in older women. *Prev Med* 2022 Jan;154:106869. PMC8724400.
118. Schousboe JT, Sprague BL, Abraham L, O'Meara ES, Onega T, Advani S, Henderson LM, **Wernli KJ**, Zhang D, Miglioretti DL, Braithwaite D, Kerlikowske. Cost-effectiveness of screening mammography beyond age 75 years: A cost-effectiveness analysis. *Ann Intern Med* 2022;175(1):11-19. PMC9621600.
119. Holman A, Kross E, Crothers K, **Wernli KJ**, Cole A, Triplette M. Patient perspectives on longitudinal adherence to lung cancer screening. *Chest* 2022;162(1):230-241. PMID: 35149081.
120. Haas CB, Hsu L, Lampe JW, **Wernli KJ**, Lindstroem S. Cross-ancestry genome-wide association studies of sex hormone concentrations in pre- and postmenopausal women. *Endocrinology* 2022;163(4): bqac020. PMC8962449.
121. Chung JR, Kim SS, Kondor RJ, Smith C, Budd AP, Tartof SY, Florea A, Talbot HK, Grijalva CG, **Wernli KJ**, Phillips CH, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Reis M, Moehling Geffel K, Nowalk MP, DaSilva J, Keong LM, Stark TJ, Barnes JR, Wentworth DE, Brammer L, Burns E, Fry AM, Patel MM, Flannery BF. Interim Estimates of 2021–22 Seasonal Influenza Vaccine Effectiveness — United States, February 2022. *MMWR Morb Mortal Wkly Rep* 2022;11;71(10):365-370. PMC8911998.
122. Li ZN, Liu F, Jefferson S, Horner L, Carney P, Johnson MDL, King JP, Martin ET, Zimmerman RK, **Wernli K**, Gaglani M, Thompson M, Flannery B, Stevens J, Tumpey T, Levine MZ. Multiplex Detection of Antibody Landscapes to SARS-CoV-2/Influenza/Common Human Coronaviruses Following Vaccination or Infection with SARS-CoV-2 and Influenza. *Clin Infect Dis* 2022;75(Supplement\_2):S271-S284. PMC9214136.
123. Kim SS, Chung JR, Talbot HK, Grijalva CG, **Wernli KJ**, Kiniry E, Martin ET, Monto AS, Belongia EA, McLean HQ, Gaglani M, Mamawala M, Nowalk MP, Geffel KM, Tartof SY, Florea A, Lee JS, Tenforde MW, Patel MM, Flannery B, and the Strain Surveillance and Emerging Variants Team. Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 21-February 2022. *Influenza Other Respir Viruses* 2022;16(6):975-985. PMC9353375.
124. Conley CC, **Wernli KJ**, Knerr S, Li T, Leppig K, Ehrlich K, Farrell D, Gao H, Bowles EJA, Graham A, Luta G, Jayasekera J, Mandelblatt JS, Schwartz M D, O'Neill SC. Using Protection Motivation Theory to predict intentions for breast cancer risk management: Intervention mechanisms from a randomized controlled trial. *J Cancer Educ.* 2023;38(1):292-300. PMC9124715.
125. Hahn EE, Ritzwoller DP, Munoz-Plaza CE, Gander J, Kushi LH, McMullen C, Oshiro C, Roblin DW, **Wernli KJ**, Staab J. Incidence and survival for patients diagnosed with breast, colorectal, and lung cancer in an integrated system. *Perm J.* 2023;27(4):129-135 PMID: 37724894.

126. Ho TH, Bissell MCS, Lee CI, Lee JM, Sprague BL, Tosteson ANA, **Wernli KJ**, Henderson LM, Kerlikowske K, Miglioretti DL. Prioritizing screening mammograms for immediate interpretation and diagnostic evaluation based on risk of recall. *J Am Coll Radiol* 2023 20(3):299-310. PMC10044471.
127. Tosteson ANA, Schifferdecker KE, Smith RE, **Wernli KJ**, Zhao W, Kaplan Cp, Buist DSM, Henderson LM, Sprague BL, Onega T, Budesky J, Jackson-Nefertiti G, Johnson D, Miglioretti D, Kerlikowske K. Women's breast cancer screening confidence by screening modality and breast density: A Breast Cancer Surveillance Consortium Survey Study. *J Womens Health* 2022; 31(11):1547-1556. PMC9700351
128. Thompson MJ, Suchsland MZ, Hardy V, Lavalley DC, Lord S, Devine EB, Jarvik JG, Findlay S, Trikalinos TA, Walter FM, Chou R, Green BB, **Wernli KJ**, Fitzpatrick AL, Bossuyt PM. Patient-centered outcomes of imaging tests: recommendations for patients, clinicians and researchers. *BMJ Qual Saf*. 2023 Sep;32(9):536-545. PMID: 34615733.
129. Jayasekera J, Zhao A, Schechter C, Lowry K, Yeh JM, Schwartz MD, O'Neill S, **Wernli KJ**, Stout N, Mandelblatt J, Kurian AW, Isaacs C. Reassessing the benefits and harms of risk-reducing medication considering the persistent risk of breast cancer mortality in estrogen receptor-positive breast cancer. *J Clin Oncol* 2023;41(4):859-870. PMID: 36455167.
130. Price AM, Flannery B, Talbot HK, Grijalva CG, **Wernli KJ**, Phillips CH, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Mutnal M, Geffel KM, Nowalk MP, Tartof SY, Florea A, McLean C, Kim SS, Patel MM, Chung JR. Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021-2022 Influenza Season. *Clin Infect Dis* 2023;76(8):1358-1363. PMC9901948.
131. Shafer L, Ahmed F, Kim S, **Wernli KJ**, Jackson ML, Nowalk MP, Bear T, Zimmerman RK, Martin ET, Monto AS, Gaglani M, Reis M, Chung JR, Flannery B, Uzicanin A. Relationship Between Telework and COVID-19 Illness with Presenteeism in a Prospective Multi-Center Study in the United States, March-November 2020. *Emerg Infect Dis* 2023; 29(2):278-285. PMC9881775.
132. Su YR, Buist DS, Lee JM, Ichikawa L, Miglioretti DL, Aiello Bowles EJ, **Wernli KJ**, Kerlikowske K, Tosteson A, Lowry KP, Henderson LM, Sprague BL, Hubbard RA. Performance of statistical and machine learning risk prediction models for surveillance benefits and failures in breast cancer survivors. *Cancer Epidemiol Biomarkers Prev* 2023;32(4):561-571. PMC10073265.
133. Lowry KP, Ichikawa L, Hubbard RA, Buist DSM, Bowles EJA, Henderson LM, Kerlikowske K, Specht JM, Sprague BL, **Wernli KJ**, Lee JM. Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status. *Cancer* 2023;129(8):1173-1182. PMC10409444.
134. Hood N, Flannery B, Gaglani M, Beeram M, **Wernli K**, Jackson ML, Martin ET, Monto AS, Zimmerman R, Raviotta J, Belongia EA, McLean HQ, Kim S, Patel M, Chung J. Influenza vaccine effectiveness among children: 2011-2020. *Pediatrics* 2023;151(4):e2022059922. PMC10071433.
135. Tartof SY, Xie F, Yadav R, **Wernli KJ**, Martin ET, Belongia EA, Gaglani M, Zimmerman RK, Talbot HK, Thornburg N, Flannery B, US Flu VE Network Investigators. Prior SARS-CoV-2 infection and COVID-19 vaccine effectiveness against outpatient illness during widespread circulation of SARS-CoV-2 Omicron variant, US Flu VE network. *Influenza Other Respir Viruses* 2023;17(5): e13143. PMC10209645.
136. Knerr S,\* Guo B, **Wernli KJ**, Mittendorf KF, Spencer Feigelson H, Gilmore MJ, Jarvik GP, Kauffman TL, Keast E, Liles EG, Lynch FL, Muessig KR, Okuyama S, Veenstra DL, Zepp JM, Wilfond BS, Devine EB, Goddard KAB. Longitudinal adherence to breast cancer surveillance following cancer genetic testing in an integrated health care system. *Breast Cancer Res Treatment* 2023;201(3):461-470. PMC10503958.
137. Lee JM, Ichikawa LE, **Wernli KJ**, Bowles EJA, Specht JM, Kerlikowske K, Miglioretti DL, Lowry KP, Tosteson ANA, Stout NK, Houssami N, Onega T, Buist DSM. Impact of surveillance mammography intervals less than one year on performance measures in women with a personal history of breast cancer. *Korean J Radiol* 2023;23(8):729-738. PMC10400369.
138. Ahmed F, Nowalk MP, Zimmerman RK, Bear T, Grijalva CG, Talbot HK, Florea A, Tartof SY, Gaglani M, Smith M, McLean HQ, King JP, Martin ET, Monto AS, Phillips CH, **Wernli KJ**, Flannery B, Chung JR,

- Uzicanin A. Work Attendance during Acute Respiratory Illness Before and During the COVID-19 Pandemic, United States, 2018–2022. *Emerg Infect Dis* 2023;29(12):2442-2450. PMC10683820.
139. Nichols HB, **Wernli KJ**, Chawla N, O’Meara ES, Figueroa Gray M, Green LE, Baggett CD, Casperson M, Chao C, Jones SMW, Kirchhoff AX, Kuo TM, Lee C, Malogolowkin M, Quesenberry CP, Ruddy KJ, Wun T, Zebrack B, Chubak J, Hahn EE, Keegan THM, Kushi LH. Challenges and Opportunities of Epidemiological Studies to Reduce the Burden of Cancers in Young Adults. *Curr Epidemiol Rep* 2023;10(3):115-124. PMC10495081.
140. Sumner KM, Yadav R, Noble EK, Sandford R, Joshi D, Tartof SY, **Wernli KJ**, Martin ET, Gaglani M, Zimmerman RK, Talbo HK, Grijalva CG, Chung JR, Rogier E, Coughlin MM, Flannery B. Anti-SARS-CoV-2 antibody levels associated with COVID-19 protections in outpatients tested for SARS-CoV-2, US Flu VE Network, October 2021-June 2022. *J Infect Dis* 2024;230(1):45-54. PMC11272097.
141. Kerlikowske K, Zhu W, Su YR, Sprague BL, Stout NK, Onega T, O’Meara ES, Henderson LM, Tosteson ANA, **Wernli K**, Miglioretti DL. Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density. *J Natl Cancer Inst*. 2024;116(2):249-25. PMC10852604.
142. Carter-Bawa L, Slaven JE, Monahan PO, Brandzel S, Gao H, **Wernli KJ**, Elston Lafata J, Rawl SM. Unpacking the Relationship Between Shared Decision-Making and Decisional Quality, Decision to Screen, and Completion in Lung Cancer Screening. *Patient Education & Counseling*. 2024 May;122:108143. doi: 10.1016/j.pec.2024.108143. PMC10922311.
143. Abrahao R, Brunson A, Chubak J, **Wernli KJ**, Nichols HB, Chao C, Ruddy KJ, Hahn EE, Li, Q, Malogolowkin MH, Sauder CAM, Kushi LH, Wun T, Keegan THM. Late venous thromboembolism in survivors in adolescent and young adult cancer: A population-based study in California. *Thrombosis Res*. 2024 Mar;235:1-7. PMC10989999.
144. Frutos AM, Price AM, Harker E, Reeves EL, Ahmad HM, Murugan V, Martin ET, House S, Saade EA, Zimmerman RK, Gaglani M, **Wernli KJ**, Walter EB, Michaels MG, Staat MA, Weinberg GA, Selvarangan R, Boom JA, Klein EJ, Halasa NB, Ginde AA, Gibbs KW, Zhu Y, Self WH, Tartof SY, Klein NP, Dascomb K, DeSilva MB, Weber Za, Yang DH, Ball SW, Surie D, DeCuir J, Dawood FS, Moline HL, Toepfer AP, Clopper BR, Link-Gelles R, Payne AB, Chung JR, Flannery B, Lewis NM, Olson SM, Adams K, Tenforde MW, Garg S, Grohskopf LA, Reed C, Ellington S, CDC Influenza Vaccine Effectiveness Collaborators. Interim estimates of 2023-2024 seasonal influenza vaccine effectiveness-United States. *MMWR Morb Mortal Wkly Rep* 2024;73(8):168-174. PMC10907036
145. Head M, Cohn B, **Wernli KJ**, Palazzo L, Ehrlich K, Matson A, Knerr S. Young women’s perspectives on being screened for hereditary breast and ovarian cancer risk during routine primary care. *Women’s Health Issues* 2024;34(3):268-275. PMC11116046.
146. Hubbard RA, Su YR, Bowles EJ, Ichikawa L, Kerlikowske K, Lowry KP, Miglioretti DL, Tosteson ANA, **Wernli KJ**, Lee JM. Predicting five-year interval second breast cancer risk in women with prior breast cancer. *J Natl Cancer Inst* 2024;116(6):929-937. PMC11160498.
147. Luce C, Palazzo L, Anderson ML, Carter-Bawa L, Gao H, Green BB, Ralston J, Rogers K, Su, YR, Tuzzio L, Triplette M, **Wernli KJ**. A pragmatic randomized clinical trial of multilevel interventions to improve adherence to lung cancer screening (The Larch Study): Study protocol. *Contemp Clin Trials* 2024;140:10749. PMC11065591.
148. Haas CB, Chen H, Harrison T, Fan S, Gago-Dominguez M, Castela JE, Bolla MK, Wang Q, Dennis J, Michailidou K, Dunning AM, Easton DF, Antoniou AC, Hall P, Czene K, Andrulis IL, Mulligan AM, Milne RL, Fasching PA, Haeberle L, Garcia-Closas M, Ahearn T, Gierach GL, Haiman C, Maskarinec G, Couch FJ, Olson JE, John EM, Chenevix-Trench G, de Gonzalez AB, Jones M, Stone J, Murphy R, Aronson KJ, **Wernli KJ**, Hsu L, Vachon C, Tamimi RM, Lindström S. Disentangling the relationships of body mass index and circulating sex hormone concentrations in mammographic density using Mendelian randomization. *Breast Cancer Res Treat* 2024;206(2):295-305. PMID: 38653906
149. **Wernli KJ**, Haupt EC, Chawla N, Osuji T, Shen E, Smitherman A, Casperson M, Kirchhoff AC, Zebrack BJ, Keegan TMH, Kushi L, Baggett C, Kaddas HK, Ruddy K, Sauder CAM, Wun T, Figueroa Gray M,

- Chubak J, Nichols HB, Hahn EE. Emergency department use in adolescent and young adults (AYA) cancer survivors from 2006-2020. *J Adolesc Young Adult Oncol* 2024;13(5):738-747. PMID: 38682323
150. Smith RE, Sprague BL, Henderson LM, Kerlikowske K, Miglioretti DL, **Wernli KJ**, Onega T, DiFlorio-Alexander RM, Tosteson ANA. Breast Density Knowledge and Willingness to Delay Treatment for Additional Breast Cancer Testing Among Women with a Personal History of Breast Cancer. *Breast Cancer Res* 2024;26(1):73. PMID: 38685119
151. Bi Q, Dickerman BA, Nguyen HQ, Martin ET, Gaglani M, **Wernli KJ**, Balasubramani GK, Flannery B, Lipsitch M, Cobey S: US Flu Vaccine Effectiveness Network Investigators. Reduced effectiveness of repeat influenza vaccination: distinguishing among within-season waning, recent clinical infection, and subclinical infection. *J Infect Dis* 2024;230(6):1309-1318. PMC11646584.
152. Chung JR, Shirk P, Gaglani M, Mutnal MB, Nowalk MP, Geffel KM, House SL, Curley T, **Wernli KJ**, Kiniry EL, Martin ET, Vaughna IA, Murugan V, Lim ES, Saade E, Faryar K, Williams OL, Walter EB, Price AM, Barnes JR, DaSilva J, Kondor R, Ellington S, Flannery B. Late-season influenza vaccine effectiveness against medically attended outpatient illness, United States, December 2022-April 2023. *Influenza Other Respir Viruses* 2024;18(6):e13342. PMID: 38923314
153. Lee JM, Ichikawa L, Kerlikowske K, Buist DSM, Lee CI, Sprague BL, Henderson LM, Onega T, **Wernli KJ**, Lowry KP, Stout NK, Tosteson ANA, Miglioretti DL. Relative timing of mammography and MRI for breast cancer screening: Impact on performance evaluation. *J Am Coll Radiol.* 2024;21(11):1722-1732. PMC12175960.
154. Sandford R, Yadav R, Noble EK, Sumner K, Joshi D, Tartof SY, **Wernli KJ**, Martin ET, Gaglani M, Zimmerman RK, Talbot HK, Grijalva CG, Belongia EA, Carlson C, Coughlin M, Flannery B, Pearce B, Rogier E. Antibody response to symptomatic infection with SARS-CoV-2 omicron variant viruses, December 2021-June 2022. *Influenza Other Respir Viruses.* 2024;18(7): e13339. PMC11250392.
155. Stout NK, Miglioretti DL, Su YR, Lee CI, Abraham L, Alagoz O, de Koning HJ, Hampton JM, Henderson L, Lowry KP, Mandelblatt JS, Onega T, Schechter CB, Sprague BI, Stein S, Trentham-Dietz A, van Ravesteyn NT, **Wernli KJ**, Kerlikowske K, Tosteson ANA. Breast cancer screening using mammography, digital breast tomosynthesis, and magnetic resonance imaging by breast density. *JAMA Intern Med* 2024;184(10):1222-1231. PMC11348087.
156. Figueroa Gray MS, Shapiro L, Dorsey CN, Randall S, Casperson M, Chawla N, Zebrack B, Fujii M, Hahn EE, Keegan THM, Kirchhoff AC, Kushi LH, Nichols HB, **Wernli KJ**, Sauder CAM, Chubak J. A patient-centered conceptual model of AYA cancer survivorship informed by a qualitative interview study. *Cancers (Basel).* 2024;16(17):3073. PMC11394144.
157. Chung JR, Price AM, Zimmerman RK, Geffel KM, House SL, Curley T, **Wernli KJ**, Phillips CH, Martin ET, Vaughn IA, Murugan V, Scotch M, Saade EA, Faryar KA, Gaglani M, Ramm JD, Williams OL, Walter EB, Kirby M, Keong LM, Kondor R, Ellington SR, Flannery B, US Flu VE Network Investigators. Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-2024 season. *Clin Infect Dis.* 2025 Nov 6;81(4):e184-e191. PMC12287938.
158. Frutos AM, Cleary S, Reeves EL, Ahmad HM, Price AM, Self WH, Zhu Y, Safdar B, Peltan ID, Gibbs KW, Exline MC, Luring AS, Ball SW, DeSilva M, Tartof SY, Dascomb K, Irving SA, Klein NP, Dixon BE, Ong TC, Vaughn IA, House SL, Faryar KA, Nowalk MP, Gaglani M, **Wernli KJ**, Murugan V, Williams OL, Selvaranga R, Weinberg GA, Staat MA, Halasa NB, Sahni LC, Michaels MG, Englund JA, Kirby MK, Surie D, Dawood FS, Clopper BR, Moline HL, Link-Gelles R, Payne AB, Harker E, Wielgosz K, Weber ZA, Yang DH, Lewis NM, DeCuir J, Olson SM, Chung JR, Flannery B, Grohskopf LA, Reed C, Garg S, Ellington S; CDC Influenza Vaccine Effectiveness Collaborators. Interim estimates of 2024-2025 seasonal influenza vaccine effectiveness- Four vaccine effectiveness networks, United States, October 2024-February 2025. *MMWR Morb Mortal Wkly Rep.* 2025;74(6):83-90. PMC11867582.
159. \*\*Hahn EE, Haupt EC, Chawla N, Osuji T, Shen E, Smitherman AB, Casperson M, Kirchhoff AC, Zebrack BJ, Lauren C, Keegan THM, Abrahão R, Ruddy KJ, Chubak J, Nichols H, **Wernli KJ**. Transitions within and use of outpatient primary and oncology care in survivors of adolescent and young adult-onset cancers. *J Oncol Practice.* 2025:OP2400886. PMC12354005.

160. Carter-Bawa L, Elston Lafata J, Slaven JE Jr, Monahan PO, Vielma AG, **Wernli KJ**, Brandzel S, Gao H, Rawl SM. Navigating shared decision-making in lung cancer screening: Insights into barriers, training, and referral propensity among clinicians. *Patient Educ Couns*. 2025 140:109303. PMC12824888.
161. **Wernli KJ**, Anderson ML, Palazzo L, Luce C, Bezman N, Chin M, Gao H, Ralston JD, Rogers K, Su YR, Triplette M, Carter-Bawa L, Vasavada A, Jordan M, West, M, Boler S, Green BB. Effectiveness of health communication intervention to improve knowledge of timeliness to return for annual lung cancer screening: The Larch Trial. *CHEST* 2026;169(2):550-561 PMID: 40939933  
 \*Podcast interview of findings with journal: <https://www.chestnet.org/guidelines-and-topic-collections/media-galleries/chest-journal-podcast/effectiveness-of-health-communication-intervention-to-improve-knowledge-on-timeliness-to-return-for-annual-lung-cancer-screening-the-larch-trial>
162. Nowalk MP, Balasubramani GK, D'Agostini H, Zimmerman RK, Monto AS, Martin ET, Nguyen HQ, Gaglani M, Mamawala M, Tartof S, Lewin BJ, **Wernli K**, Wickersham B, Talbot HK, Grijalva CG, Chung JR, Flannery B, US Flu VE Network Investigators. Does home COVID-19 testing bias COVID-19 vaccine effectiveness estimates? *Am J Prev Med*. 2026 Jan;70(1):108096. PMC12690486.
163. Parker K, Heneghan MB, Li QW, Brunson A, Ou J, Kaddas HK, Abrahao R, Chubak J, **Wernli KJ**, Zebrack B, Hahn EE, Kushi L, Nichols HB, Keegan TMH, Kirchoff AC. Identifying clustering in patterns of late effects among survivors of adolescent and young adult Hodgkin lymphoma. *JNCI Cancer Spectr*. 2025 Nov 3;9(6). PMC12628312.
164. Louie T, Snidarich M, Hippe DS, **Wernli KJ**, Palazzo L, Hansell L, Brown M, Coronado GD, Lodhi S, Leone R, DeCell K, Mardesich K, Wysham N, Triplette M. A pragmatic pre-post intervention trial to address the adherence to lung cancer screening follow-up in community settings (the ACCELL trial): Study protocol. *Contemp Clin Trials*. 2025 Dec;159:108106. PMC12560967.
165. Biddle JE, House S, Kwon JH, Presti RM, Fritz SA, Curley T, McLaren SH, Stockwell MS, Schmitz J, Talbot HK, Grijalva CG, Saade EA, Albar Z, Murugan V, Cruz RA, Martin ET, Vaughn IA, Wernli KJ, Wickerhsam BM, Zimmerman RK, Geffel KM, Gaglani M, Smith ME, Walter EB, Bontrager NAB, Bristol L, Price AM, Chung JR, Flannery B, Rolfes MA, Mellis AM, RVTHN-Flu Study, US Flu VE Network Investigators. *Epidemics* 2026 (epub). PMID: 41547041
166. Jones S, Keegan TMH, Hahn E, Nichols H, O'Meara E, Figueroa Gray M, **Wernli KJ**, Sauder C, Kirchoff A, Laurent C, Kushi L, Chubak J. Test-retest reliability and mode effects on single item and multi-item in a survey of adolescent and young adults with cancer. In press, *J Adolesc Young Adult Oncol*
167. Walsh C, Palazzo L, Hansel L, Louie T, Long S, Brown M, Hippe D, Coronado G, DeCell K, Leone R, Lodhi S, Wysham N, **Wernli KJ**, Triplette M. Lung cancer screening care pathways in community settings: An examination of three healthcare systems. In press, *Annals of ATS*
168. \*Vasavada A, Palazzo L, Luce C, Sanchez M, Triplette M, Ralston JD, Carter-Bawa L, Green BB, Gao H, Li CI, Anderson ML, Su YR, Rogers K, **Wernli KJ**. "It's coming whether we want it to or not": A qualitative exploration of older adults' comfort with and perceptions of technology and digital health. *Res Sq*. 2025 Nov 19;. PMC12668164.

### ***Manuscript under review***

1. \*Vasavada A, Triplette M, Palazzo L, Ralston J, Carter-Bawa L, Luce C, Green BB, Gao H, Anderson ML, Su YR, Rogers K, **Wernli KJ**. Is anybody out there? Understanding the reach of lung cancer screening health communication through EHR patient portal. Revise and resubmit, *J Health Communication*
2. **Wernli KJ**, Ichikawa L, Palazzo L, Luce C, Hudson M, Smieliauskas F, Edge S. Real-world quality in resolution of positive findings in lung cancer screening (Alliance A23\_Pilot9). Under review, *CHEST Pulmonary*.
3. **Wernli KJ**, Anderson ML, Palazzo L, Luce C, Bezman N, Rogers K, Chin M, Gao H, Ralston J, Su YR, Carter-Bawa L, Triplette M, Tuzzio L, Vasavada A, Green BB. Health communication and reminder intervention for lung cancer screening: Larch Trial. Under review, *JAMA Internal Med*.

4. Maloney P, Reeves EL, Wielgosz K, Price AM, Natarajan K, DeSilva MB, Dascomb K, Klein NP, Tartof SY, Irving SA, Grannis SH, Ong TC, Weber ZA, Schuster JE, Zerr DM, Michaels MG, Boom JA, Halaza NB, Staat MA, Weinberg GA, House SL, Saade EA, Geffell KM, Gagliani M, **Wernli KJ**, Murugan V, Martine ET, Bontrager NAB, Kirby MK, Payne AB, Dawood FS, Tanni A, Moline HL, Zhao K, Adams K, DeCuir J, Olson SM, Chung JR, Lewis N, Flannery B, Reed C, Garg S, Ellington S, CDC Influenza Vaccine Effectiveness Collaborators. Interim estimates of 2025-2026 seasonal influenza vaccine effectiveness—United States, September 2025-February 2026. Under review, MMWR Morb Mortal Wkly Rep

### **Refereed Reports**

1. **Wernli KJ**, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Whitlock E. Skin Cancer in Adults: Screening. Evidence Report/Technology Assessment No. 14-05210-EF-1(Prepared by Kaiser Permanente Research Affiliates Evidence-based Practice Center under Contract No. HHS290201200015i) Rockville, MD: Agency for Healthcare Research and Quality; 2016. PMID: 27583318
2. **Wernli K**, Brandzel S, Buist D, Bush M, DeMartini W, Ichikawa L, Haas C, Henderson L, Johnson D, Kerlikowske K, McColgin D, Miglioretti D, Nekhlyudov L, Onega T, Rosenberg D. Is Breast MRI Better at Finding Second Breast Cancers than Mammograms Alone for Breast Cancer Survivors? [Internet]. Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2019 May. PMID: 32453519.
3. Miglioretti DL, Onega T, Su Y, Zhu W, Stout NK, **Wernli KJ**, Bissell MCS, de Bie E, Lowry KP, Sprague B, Ho TQH, Schifferdecker KE, Kerlikowske K, Tosteson ANA, for the Breast Cancer Surveillance Consortium. Comparing the Effectiveness of Breast Cancer Screening and Diagnostic Tests among Women with Different Breast Densities—The BCSC-ADVANCE Study. Patient-Centered Outcomes Research Institute (PCORI). 2023

### **Non-refereed research articles**

1. Astrakianakis G, Seixas NS, Ray RM, Camp JE, Gao DL, Feng Z, Li W, **Wernli KJ**, Fitzgibbons ED, Thomas DB, Checkoway H. Re: Lung cancer risk among female textile workers exposed to endotoxin. J Natl Cancer Inst 2010 Jun 16;102(12):913-4. PMC6281137.
2. Braithwaite D, **Wernli KJ**, Anton-Culver H, Engstrom P, Greenberg ER, Meyskens F. Opportunities for cancer epidemiology and control in low- and middle-income countries: A report from the ASPO International Cancer Prevention Interest Group. Cancer Epidemiol Biomarkers Prev 2010;19(7):1665-1667. PMID: 20615883
3. Carlos RC, Buist DS, **Wernli KJ**, Swan JS. Patient-centered outcomes in imaging: quantifying value. J Am Coll Radiology 2012;9(10):725-728. PMC3810945
4. **Wernli KJ**, Inadomi JM. Anesthesia for colonoscopy: too much of a good thing? JAMA Intern Med 2013;173(9):807-816. PMID: 23479078
5. **Wernli KJ**, Brenner A, Rutter CM, Inadomi JM. Response to sedation and colonoscopy. Gastroenterology 2016;151(3):564 PMID: 27496674
6. Kerlikowske K, Zhu W, Su YR, Sprague BL, O'Meara ES, Tosteson ANA, **Wernli KJ**, Miglioretti DL. Response to Omoleye, Esserman, Olufunmilayo. J Natl Cancer Inst 2024;116(4):629-630 PMID: 38230817

### **Book Chapters**

1. Newcomb PA, **Wernli KJ**. Risk Factors. In Breast Cancer: Risk Reduction and Early Detection Strategies. Edited by E. Sauter and M. Daly. Springer. New York City, 2010, pages 3-22.
2. **Wernli KJ**, Inadomi J. Sedation issues in colonoscopy: quality and economic considerations. In Colorectal Cancer Screening. Edited by J. Allen and S. Haukat. Springer. New York City, 2015, 141-151.

3. **Wernli KJ**, Bowles EA. Breast cancer screening: evidence and recommendations. In Rotation in Radiology: Breast Imaging. Edited by C. Lee, C. Lehman, and L. Bassett. Oxford University Press, 2018, 14-18.

### **Published Technical Reports**

1. Lavalley DC, Gore JL, Lawrence SO, Lindsay J, Marsh S, Scott MR, **Wernli K**. Initiative to Support Patient Involvement in Research (INSPIRE): Findings from Phase I Interviews [Internet]. September 2016. Available from: [https://www.ipfcc.org/bestpractices/sustainable-partnerships/tools/INSPIRE\\_phase\\_i\\_report\\_final\\_20160930.pdf](https://www.ipfcc.org/bestpractices/sustainable-partnerships/tools/INSPIRE_phase_i_report_final_20160930.pdf)
2. Lavalley DC, Gore JL, Lawrence SO, Lindsay J, Marsh S, Scott MR, **Wernli K**. Initiative to Support Patient Involvement in Research (INSPIRE): Community Workshop Report [Internet]. October 2016. Available from: [https://www.ipfcc.org/bestpractices/sustainable-partnerships/tools/INSPIRE\\_pcor\\_workshop\\_summary\\_final\\_20161005.pdf](https://www.ipfcc.org/bestpractices/sustainable-partnerships/tools/INSPIRE_pcor_workshop_summary_final_20161005.pdf)

### **Published abstracts**

1. **Wernli K**, Hubbard R, Johnson E, Chubak J, Kamineni A, Rutter C. A2-1: Patterns of colorectal cancer testing in men and women newly eligible screening. *Clin Med Res* 2013;11(3):123.
2. **Wernli KJ**, Arao RF, Hubbard RA, Sprague B, Alford-Teaster J, Haas J, Henderson L, Hill D, Lee C, Tosteson A, Onega T. How have breast cancer screening intervals changed since the 2009 USPSTF guideline update? *Cancer Epidemiol Biomark Prev* 2016;25:558.
3. **Wernli KJ**, Callaway KA, Henderson LM, Kerlikowske K, Lee JM, Ross-Degnan D, Wallace JK, Wharam JF, Zhang F, Stout NK. Trends in breast MRI use among women with BRCA mutations: A national claims analysis 2006-2016. *Cancer Epidemiol Biomark Prev* 2019;28(3):624.
4. Tuzzio L, Palazzo L, Brush S, Ehrlich K, Anderson M, Gao H, **Wernli KJ**. Co-designing cancer screening interventions with people over 55 years old at risk for lung cancer. *Innovation in Aging*, Volume 3, Issue Supplement\_1, November 2019, Pages S917–S918.
5. **Wernli KJ**, Tuzzio L, Brush SA, Ehrlich K, Gao H, Anderson M, Palazzo L. Understanding Stakeholder Perspectives in Developing User-Centered Design Interventions to Improve Lung Cancer Screening Adherence at Kaiser Permanente Washington. *Am J Respir Crit Care Med* 2020;201:A5942.
6. **Wernli KJ**, Callaway KA, Henderson LM, Kerlikowske K, Lee JM, Ross-Degnan D, Wallace JK, Wharam JF, Zhang F, Stout NK. Trends in breast MRI use among women with BRCA mutations: A national claims analysis 2006-2016. *Cancer Epidemiol Biomark Prev* 2019;28(3):624

### **Media coverage (in last 10 years)**

#### **Breast magnetic resonance imaging use in community practice**

- *Aunt Minnie*, Oct 1, 2020 [Breast MRI use is up, but is it appropriate?](#)
- *The Imaging Wire*, Oct 5, 2020 [Breast MRI up, but some underscreened](#)
- *Kaiser Permanente Washington Health Research Institute*, Oct 7, 2020. [Which women are receiving breast MRI to screen for breast cancer?](#)
- Patient from Hell Podcast. [Episode 58: The Complexity of Breast Density & Breast Cancer Imaging with Karen Wernli, PhD](#) (April 2024)

#### **Patient and stakeholder engagement**

- Group Health Research Institute Blog: (02/10/2016). [Patients power SIMBA research on breast cancer, mammograms and breast MRIs](#)
- [Group Health Research Institute] (02/16/2016). *Making Medicine Better By Working Together*. [Video File]. Retrieved from [https://youtube/llsYo\\_pqyZQ](https://youtube/llsYo_pqyZQ)
- Anyanwu C and Hemphill R. [Finding and recruiting research partners; lessons from PCORI awardees](#). September 1, 2017.

### **Short-term risks associated with general anesthesia during colonoscopy compared to conscious sedation in US adult population**

- American Gastroenterological Association, Jan 26, 2016. [Colonoscopy risk increases with anesthesia](#)
- [GI & Hepatology News] (2016, March 31). Risks associated with anesthesia services during colonoscopy. [Video file]. Retrieved from: <https://www.youtube.com/watch?v=k41P0QUGUpo>
- A Woman's Health, Apr 7, 2015. [Anesthesia increases colonoscopy risks.](#)
- Healio Gastroenterology, Mar 30, 2016. Risk for complications after colonoscopy increase

### **Lung cancer screening**

- Group Health Research Institute Blog: Nazarko J. (01/08/2016). [Group Health's new lung cancer screening program shows promise](#)
- Group Health Research Institute Blog: Brandzel (03/11/2016). [Patients and providers talk about lung cancer screening, GHRI listens](#)
- Kaiser Permanente Washington Health Research Institute (07/28/2020). [Lung cancer screening is changing](#)
- Kaiser Permanente Washington Health Research Institute (07/09/2021). [Patient collaboration sparks care innovations.](#)
- Kaiser Permanente Washington Health Research Institute (09/19/2025). [Helping first-time screeners know when to return.](#)
- CHEST Journal Podcasts (02/02/2026). [Effectiveness of lung cancer screening intervention to improve knowledge of timeliness to return to annual lung cancer screening.](#)

### **Health care utilization in adolescent and young adult (AYA) cancer patients**

- Group Health Research Institute Blog, Wernli KJ (05/16/2016). [For young adults with cancer, the Clare Project asks: what matters most.](#)
- Pallimed: A Hospice & Palliative Medicine Blog (06/29/2016): [The Clare Project and "What Matters most?" to young people with advanced cancer.](#)
- KP Washington Health Research Institute (6/29/2017): [What young adults with advanced cancer are telling The Clare Project.](#)
- Kaiser Permanente Washington Health Research Institute (11/19/2018): [Young adults with cancer speak about balancing hope and risk.](#)
- Kaiser Permanente Washington Health Research Institute (04/29/2024): [Study sheds light on needs of young people with cancer.](#)
- Cure (5/10/2024): [Emergency department use common among AYA survivors](#)
- Kaiser Permanente Washington Health Research Institute (10/22/2024): [Supporting young adults through cancer and beyond](#)

### **Breast cancer surveillance imaging**

- FastCo Design. Wilson, M (6/22/16). [Post-cancer checkups are stressful – this decision aid is designed to help.](#)
- Artefact (6/20/2016). [SIMBA Decision Aid.](#)
- Patient-Centered Outcomes Research Institute Blog (10/3/16). [Helping survivors of breast cancer watch out for recurrences.](#)
- [Patient Centered Outcomes Research Institute] (2016 October 3). Helping breast cancer survivors watch out for recurrences. [Video file]. Retrieved from <http://www.pcori.org/blog/helping-survivors-breast-cancer-watch-out-recurrences>
- Kaiser Permanente Washington Health Research Institute (2/28/17). [Patient-researcher helps advance care for other breast cancer survivors.](#)
- Kaiser Permanente Washington Health Research Institute (3/10/17). [Breast cancer screening choice made easier by research-design team.](#)
- Kaiser Permanente Washington Health Research Institute (6/4/19). [Using breast MRI after cancer may lead to unneeded biopsies.](#)

- Reuters (via Medscape; 6/7/19). [Breast MRI may up biopsy, cancer-detection rates in women with breast cancer history.](#)
- HealthDay (syndicated, including [U.S. News & World Report](#) and [WebMD](#); 6/4/19). [Is MRI screening worth it for breast cancer survivors?](#)
- Aunt Minnie (6/4/19). [Surveillance breast MRI is double-edged sword.](#) [Patient Centered Outcomes Research Institute] (2021 November 16). Getting Buy-In Before Results. [Video file]. Available from <https://www.pcori.org/video/getting-buy-results>.
- Patient from Hell Podcast. [Episode 40: Navigating Breast Survivorship with Karen Wernli, PhD](#) (October 2023).

## BRCA Testing

- HemeOnc Today (7/16/2019). [BRCA testing underutilized despite access, coverage.](#)

## INVITED PRESENTATIONS (in the last 10 years)

### *Contributed national oral presentations*

1. **Wernli KJ**, Arao RF, Hubbard RA, Sprague B, Alford-Teaster J, Haas J, Henderson L, Hill D, Lee C, Tosteson A, Onega T. How have breast cancer screening intervals changed since the 2009 USPSTF guideline update? American Society for Preventive Oncology, Columbus, OH, March 2016
2. **Wernli KJ**, Callaway KA, Henderson LM, Kerlikowske K, Lee JM, Ross-Degnan D, Wallace JK, Wharam JF, Zhang F, Stout NK. Trends in breast MRI use among women with BRCA mutations: A national claims analysis 2006-2016. American Society for Preventive Oncology, Tampa, FL, March 2019.
3. Callaway KA, Zhang F, **Wernli KJ**, Henderson LM, Kerlikowske K, Lee JM, Ross-Degnan D, Wallace JK, Wharam JF, Stout NK. Impact of Breast Density Notification Legislation on Ultrasound and MRI Use, 2002-2016. The 9th International Breast Density & Cancer Risk Assessment Workshop, Honolulu, HI, June 2019.
4. **Wernli KJ**, Tuzzio L, Brush S, Ehrlich K, Gao H, Anderson ML, Palazzo L. Understanding stakeholder perspectives in developing user-centered design interventions in lung cancer screening at KPWA. Kaiser Permanente Oncology Meeting, Los Angeles, CA, November 2019.
5. Vasavada A, Palazzo L, Triplette M, Gao H, Anderson ML, Luce C, Su YR, Ralston J, Rogers K, Bezman N, Green BB, Carter-Bawa L, **Wernli KJ**. Effectiveness of delivery of lung cancer screening educational communication through EHR patient portal. American Society for Preventive Oncology, Philadelphia, PA, April 2025.
6. **Wernli KJ**, Anderson ML, Palazzo L, Luce C, Bezman N, Rogers K, Chin M, Gao H, Ralston J, Su YR, Carter-Bawa L, Triplette M, Tuzzio L, Vasavada A, Green BB. Pragmatic clinical trial of two patient-centered, multilevel interventions to improve annual lung cancer screening. American Thoracic Society, Orlando, FL, May 2026.

### *Contributed international oral presentations*

1. Sansom-Daly U, Darlington A, Poort H, Rosenberg A, Weaver M, Mack J, Haase J, Phillips-Salimi C, **Wernli KJ**, Wakefield C, Girgis A, Fernando R, Donovan L, Trethewie S, Herbert A, Fair D, Kirchoff A, Lindsay T, Anazodo A, Schulte F, Cohn R, Mosher P, Al-Awamer A, Sue L, and Wiener L. Understanding and addressing the training needs of clinicians to improve end-of-life care for adolescents and young adults with cancer worldwide. 3rd Global AYA Cancer Congress, Sydney, Australia, December 2018.

### *Selected contributed national poster presentations*

1. **Wernli KJ**, Kamineni A, Johnson E, Shortreed SM, Green BB, Chubak J, Rutter CM. Current patterns of colorectal cancer screening in an insured population. American Society for Preventive Oncology, Columbus, OH, March 2016.
2. **Wernli KJ** and Artefact. Designing for good patient decisions: bringing together data, psychology, and human-centered design to help breast cancer survivors chose a method for post-treatment surveillance. Stanford Medicine X, Palo Alto, CA, September 2016.
3. **Wernli KJ**, Ichikawa I, Kerlikowske K, Bush M, Johnson D, Buist DSM, Brandzel SD, DeMartini WB, Henderson L, Nekhlyudov L, Onega T, Sprague B, Miglioretti DL. Comparative performance of surveillance mammography and breast MRI in women with a history of breast cancer. The San Antonio Breast Cancer Symposium, San Antonio, TX, December 2016.
4. Knerr S, **Wernli KJ**, Leppig K, Ehrlich K, Graham AL, Farrell D, Evans C, Schwartz MD, O'Neill SC. Developing a scalable decision support tool for women with dense breasts: early efforts to facilitate patient uptake and clinical integration. Science of Dissemination and Implementation, Washington DC, December 2016
5. Figueroa Gray M, Ludman EJ, Beatty TC, **Wernli KJ**. Using Twitter for recruitment, patient engagement, and data collection in a study about adolescent and young adults with late-stage cancer. American Society for Preventive Oncology, Seattle, WA, March 2017.
6. Figueroa Gray M, Ludman EJ, Beatty TC, **Wernli KJ**. Balancing hope and risk for adolescent and young adult cancer patients with late-stage cancer. American Society for Preventive Oncology, Seattle, WA, March 2017.
7. Haas C, **Wernli KJ**, Phipps A, Hajat A, Kamineni A, Chubak J. Disparities in completion of fecal immunochemical tests for colorectal cancer screening in a health maintenance organization setting. American Society for Preventive Oncology, Seattle, WA, March 2017.
8. Figueroa Gray M, Ludman EJ, Beatty TC, **Wernli KJ**. Using Twitter for recruitment, patient engagement, and data collection in a study about adolescent and young adults with late-stage cancer. Pacific Northwest Palliative Care Conference, Seattle, WA, April 2017.
9. Figueroa Gray M, Ludman EJ, Beatty TC, **Wernli KJ**. Balancing hope and risk for adolescent and young adult cancer patients with late-stage cancer. Pacific Northwest Palliative Care Conference, Seattle, WA, April 2017.
10. Haas C, **Wernli KJ**, Phipps A, Hajat A, Kamineni A, Chubak J. Disparities in completion of fecal immunochemical tests for colorectal cancer screening in a health maintenance organization setting. Society for Epidemiologic Research, Seattle, WA, June 2017.
11. **Wernli KJ**, Bowles EA, Evans C, Gao H, Hansen K, Knerr S, Leppig K, Schwartz MD, O'Neill SC. Patient characteristics associated with participation in a web-based decision support trial for women at increased breast cancer risk: ENGAGED 2 trial. American Society for Preventive Oncology, New York, NY March 2018.
12. **Wernli KJ**, O'Meara ES, Delaney K, Chen L, Farjah F, Beatty T, Zehra R, Hwee S, Mack JW. End of life care in a national sample of adolescent and young adult cancer patients, 2001-2016. AcademyHealth, Seattle, WA, June 2018.
13. Hwee S, O'Meara ES, Helfrich C, Smitherman A, Delaney K, Chen L, Beatty T, Zehra R, **Wernli KJ**. U.S. Opioid Prescribing Trends for Adolescent and Young Adult Cancer Patients in Last Year of Life, 2001 - 2016: A Study from the Clare Project. AcademyHealth, Seattle, WA, June 2018.
14. Knerr S, Bowles E, **Wernli KJ**, Schwartz M, O'Neill S. Association between health literacy and baseline breast density awareness in a health-system embedded intervention efficacy study. American Society for Preventive Oncology, Tampa, FL, March 2019.
15. **Wernli KJ**, Evers S, Berthoud H, Norris C, Rosenberg D. Peer support needs of young adult patients with self-identified complex medical conditions: Opportunities for improved connection with clinical care. Healthcare Systems Research Network, Portland, OR, April 2019.

16. **Wernli KJ**, Beatty T, O'Meara EO, Delaney K, Farjah F, Mack JW. Use of national claims data to inform AYA oncology: focus on end of life. Childhood Cancer Data Initiative Symposium. Washington DC, July 2019.
17. Tuzzio L, Palazzo L, Brush S, Ehrlich K, Anderson M, Gao H, **Wernli KJ**. Co-designing cancer screening interventions with people over 55 years old at risk for lung cancer. Gerontology Society of America Conference, Austin, TX, November 2019.
18. **Wernli KJ**, Knerr S, Li T, Leppig K, Ehrlich K, Farrell D, Gao H, Bowles EJA, Graham AL, Luta G, Mandelblatt JS, Schwartz MD, O'Neill SC. Randomized trial of a web-based personalized breast cancer risk communication and decision support tool on clinical prevention outcomes. American Society for Preventive Oncology, Tucson, AZ, March 2020.
19. **Wernli KJ**, Tuzzio L, Luce C, West M, Jordan M, Boler S, Triplette M, Carter-Bawa L, Green B, Rogers K, Gao H, Su YR, Anderson M, Ralston J, Palazzo L. Development of a patient-centered intervention to improve annual adherence to lung cancer screening using human-centered design—Patient Voices Video. National Lung Cancer Roundtable, Washington DC, December 2022
20. Rogers K, **Wernli KJ**, Luce C, Palazzo L, Chin M, Tutt TP, Bezman N, Green B, Gao H, Anderson M, Su YR, Ralston J. How to develop HER-based interventions in health services research: Guidance from the Larch Study. AcademyHealth, Seattle WA, June 2023
21. **Wernli KJ**, Tuzzio L, Luce C, West M, Jordan M, Boler S, Triplette M, Carter-Bawa L, Green B, Rogers K, Gao H, Su YR, Anderson M, Ralston J, Palazzo L. Development of a patient-centered intervention to improve annual adherence to lung cancer screening using human-centered design—Patient Voices Video. AcademyHealth, Seattle WA, June 2023
22. **Wernli KJ**, Palazzo L, Ichikawa L, Luce C, Singh U, Shea M, Hudson M, Smieliauskas F, Edge S. Mixed methods study of quality in time to biopsy and lung cancer diagnosis (Alliance A23\_Pilot9). AcademyHealth, Seattle WA, June 2023
23. **Wernli KJ**, Anderson ML, Luce C, Gao H, Su YR, Palazzo L, Ralston JD, Rogers K, Bezman N, Carter-Bawa L, Triplette M, Vasavada A, Green BB. Video intervention improves patient knowledge of timeliness to return for annual lung cancer screening. American Society for Preventive Oncology, Chicago, IL, March 2024.
24. Vasavada A, Palazzo L, Triplette M, Gao H, Anderson ML, Luce C, Su YR, Ralston J, Rogers K, Bezman N, Green BB, Carter-Bawa L, **Wernli KJ**. Reach of digital interventions to address disparities in repeat lung cancer screening in Washington State. American Association of Cancer Research Health Disparities Conference. Los Angeles, CA, September 2024
25. **Wernli KJ**, Haupt EC, Smitherman AB, Osuji T, Shen E, Chawla N, Casperson M, Kirchhoff AC, Laurent C, Ruddy K, Keegan THM, Kaddas HK, Abrahão R, Chao C, Sauder CAM, Figueroa Gray M, Chubak J, Nichols HB, Kushi L, Hahn EE. Burden of hospitalizations in four adolescent and young adult (AYA) cancer survivor populations, 2006-2020. American Society for Preventive Oncology, Denver CO, April 2026.
26. O'Neill SC, Casperson M, Whitmore S, Lieber S, Covey A, Chavez Ochoa J, **Wernli KJ**. Connecting young adult cancer survivors to community-based peer support. American Society for Preventive Oncology, Denver CO, April 2026.

### ***Contributed international poster presentations***

1. **Wernli KJ**, Hubbard R, Johnson E, Chubak J, Kamineni A, Rutter CM. Patterns of colorectal cancer screening uptake in men and women newly-eligible for screening. International Cancer Screening Network Conference, Rotterdam, The Netherlands, June 2015.
2. Roth JA, Brandzel SD; Carter-Harris L, Buist D, **Wernli KJ**. Patient Motivations for Pursuing Low-Dose CT Lung Cancer Screening in an Integrated Healthcare System: A Qualitative Evaluation. Poster presentation at the World Congress on Lung Cancer, in Vienna, Austria, December 2016.

3. **Wernli KJ**, Gao H, Leblanc J, Nazarko J, Buist DSM. Lung cancer screening implementation in community practice: Kaiser Permanente Washington experience 2015-2018. International Association for the Study of Lung Cancer (IASLC) 19<sup>th</sup> World Conference on Lung Cancer, Toronto, Canada, September 2018.
4. **Wernli KJ**, Callaway KA, Henderson LM, Kerlikowske K, Lee JM, Ross-Degnan D, Wallace JK, Wharam JF, Zhang F, Stout NK. Trends in Screening Breast MRI Rates in US Women, 2006-2016. International Cancer Screening Network Conference, Rotterdam, The Netherlands, June 2019.
5. **Wernli KJ**, Gao H, Leblanc J, Nazarko J, Buist DSM. Lung cancer screening implementation in community practice: Kaiser Permanente Washington experience 2015-2018. International Cancer Screening Network Conference, Rotterdam, The Netherlands, June 2019.
6. **Wernli KJ**, Haupt EC, Chawla N, Osuji T, Shen E, Smitherman A, Kirchoff AC, Casperson M, Zebrack BJ, Keegan THM, Kushi LH, Baggett C, Kaddas H, Ruddy K, Sauder C, Wun T, Figueroa Gray M, Chubak J, Nichols HB, Hahn EE. Emergency department use in adolescent and young adult cancer survivors: opportunities to improve survivorship care. 5<sup>th</sup> Global Adolescent and Young Adult Cancer Congress, Long Beach CA, June 2023.
7. **Wernli KJ**, Anderson ML, Luce C, Gao H, Su YR, Palazzo L, Ralston JD, Rogers K, Bezman N, Carter-Bawa L, Triplette M, Vasavada A, Green BB. Video intervention improves patient knowledge of timeliness to return for annual lung cancer screening. International Cancer Screening Network, Aarhus, Denmark, June 2025.
8. Vasavada A, Palazzo L, Triplette M, Gao H, Anderson ML, Luce C, Su YR, Ralston J, Rogers K, Bezman N, Green BB, Carter-Bawa L, **Wernli KJ**. Reach of digital interventions to address disparities in repeat lung cancer screening in Washington State. International Cancer Screening Network, Aarhus, Denmark, June 2025.
9. **Wernli KJ**, Bishop D, Boswell T, Crippen M, Groff D, Hall S, Hohnstein S, Luce C, Vasavada A, Palazzo L. Patient engagement in lung cancer screening intervention development and program improvement, Washington USA. International Cancer Screening Network, Aarhus, Denmark, June 2025.
10. Luce C, Palazzo L, Vasavada A, Mettert K, Gao H, Ralston J, Bezman N, Green BB, Rogers K, Anderson ML, Su YR, Triplette M, Carter-Bawa L, **Wernli KJ**. Patient perspectives on the acceptability and appropriateness of two pragmatic lung cancer screening interventions designed to improve adherence in Washington, USA. International Cancer Screening Network, Aarhus, Denmark, June 2025.

### ***Invited Oral Presentations - Local***

1. **Wernli KJ**. Patient-centered approach to surveillance breast imaging: Lessons learned from SIMBA. Group Health Research Institute Seminar, Seattle, WA, July 27, 2016.
2. **Wernli KJ**. Lessons in PCORI-funded research project. University of Washington K12 Scholars, Seattle, WA, February 26, 2018.
3. Anau J, Coley RY, Grafton J, Johnson D, **Wernli KJ**. Standing on the Shoulders of Giants: Conducting research when you wish you didn't have to stand on those guys' shoulders. Kaiser Permanente Washington Health Research Institute Seminar, Seattle, WA, June 12, 2018.
4. **Wernli KJ**. Finding the confluence of patient-centered outcomes research in cancer. University of Washington, School of Nursing, Seattle, WA, April 2, 2019.
5. **Wernli KJ**. Multilevel interventions to increase adherence to lung cancer screening. The Larch Study: Developing a Video-based intervention. Bernard J. Tyson Kaiser Permanente School of Medicine, Department of Health Systems (Virtual). January 11, 2023.
6. **Wernli KJ**. Patient engagement in cancer research. Principles, methods and results. Kaiser Permanente Health Research Institute Seminar, Seattle, WA, June 6, 2024.

### ***Invited Oral Presentations - National***

1. **Wernli KJ**, Pfarr N. Informing breast cancer decisions with human-centered design. Innovative Learning Network. San Jose, CA, May 11, 2016.
2. **Wernli KJ**. Using qualitative methods to learn about confounders. The 2016 Epidemiology Congress of the Americas, Miami, FL, June 24, 2016.
3. **Wernli KJ**. What is the current state of end of life in adolescent and young adult cancer patients across the US? Dana Farber Cancer Institute, Boston, MA, October 4, 2016.
4. **Wernli KJ**. Patient-centered approach to surveillance breast imaging: Lessons learned from SIMBA. Columbia University, New York City, NY, October 6, 2016.
5. **Wernli KJ**, Bush M. Comparative effectiveness of surveillance breast imaging modalities in breast cancer survivors. In Pre-engagement in PCOR: Incorporating Lessons from the Field at Second Annual Patient Centered Outcomes Research Institute meeting, National Harbor, MD, November 19, 2016.
6. **Wernli KJ**, Miglioretti D. Patient engagement in oncology research. UC Davis Community Engagement, Sacramento, CA, November 13, 2017.
7. **Wernli KJ**. Finding the confluence of patient-centered outcomes research in cancer. University of North Carolina, Chapel Hill, February 23, 2018.
8. **Wernli KJ**. Finding the confluence of patient-centered outcomes research in cancer. Duke University, June 25, 2018.
9. **Wernli KJ**. Use of national claims data to inform AYA oncology: focus on end-of-life care. Cancer Informatics for Cancer Centers (Ci4CC) Fall 2020 Virtual Symposium. October 8, 2020.
10. **Wernli KJ**. Quality metrics in time to biopsy and lung cancer diagnosis in cancer screening population. Alliance for Oncology Clinical Trials/Cancer Care Delivery Research (CCDR) Committee. November 4, 2021.
11. **Wernli KJ**. Finding the confluence of patient-centered outcomes in breast cancer survivors. Emory University, School of Public Health, November 16, 2021.
12. **Wernli KJ**. Quality metrics in time to biopsy and lung cancer diagnosis in cancer screening population. Alliance for Oncology Clinical Trials/Cancer Care Delivery Research (CCDR) Committee. November 3, 2022.
13. **Wernli KJ**. Multilevel Interventions in Lung Cancer Screening: innovations in lessons we already learned. University of Kansas School of Medicine. Research & Discovery Ground Rounds, May 25, 2023.
14. **Wernli KJ**. Patient engagement in cancer research. Principles, methods and results. Robert C. Millikan Seminar, Department of Epidemiology, University of North Carolina, Chapel Hill. September 22, 2023.
15. **Wernli KJ**. Lung Cancer Screening with Low-Dose CT: The Gold Standard for Lung Cancer Screening. GO2 Centers of Excellence. Denver, CO. October 10, 2025.

### ***Invited Oral Presentations - International***

1. **Wernli KJ**. What is the current state of end of life in adolescent and young adult cancer patients across the US? Pediatric Oncology Group Ontario, Toronto, Canada, October 7, 2016.
2. **Wernli KJ**. Lung cancer screening in the USA Healthcare System: Kaiser Permanente Washington experience. International Agency for Research on Cancer, Lyon, France, October 7, 2019.
3. **Wernli KJ**. Patient Centered Outcomes in Oncology Research. Institute of Social and Preventive Medicine, University of Bern. December 18, 2023.
4. **Wernli KJ**. OPICO Cohort: Kaiser Permanente Washington. International Agency for Research on Cancer, Lyon, France, November 7, 2024.

### ***Plenary presentations***

1. **Wernli KJ**, Johnson D. Plenary: Straight from the Source. Panel of patient and researcher teams at First Annual PCORI Meeting. October 7, 2015.
2. **Wernli KJ**, Brandzel S, Bush M, Johnson D. Models of Patient Engagement. INSPIRE Symposium, Seattle, WA, July 19, 2016.
3. Berry A, Tuzzio L, **Wernli KJ**. Human-Centered Design Methods to Improve Health Services Research: Examples from the Field. Healthcare Systems Research Network (HCSRN) 2021 Virtual Annual Meeting; May 12, 2021.

### ***Panels***

1. Panel member at American Society for Preventive Oncology in Columbus OH. Strategies for building, prioritizing, and sustaining a research group: how to manage time and leverage available resources effectively. March 13, 2016.
2. Panel member at American Society for Preventive Oncology in Seattle, WA. A Roadmap to Academic and Research Environments: Identifying and Choosing the Best Fit for your Career Goals. March 12, 2017.
3. Panel member. K-12 Post-transition. University of Washington K12 Scholars, Seattle, WA, January 14, 2019.
4. Panel member. Patient Engagement in Research. KPWHRI K12 Catalyst Scholars, Seattle, WA, June 17, 2019.
5. Panel member. President's Cancer Panel. Improving Resilience and Equity in Cancer Screening: Innovation to Increase Screening. February 11, 2021.
6. Panel Member. National Lung Cancer Roundtable: Early Detection Implementation Strategies Task Group, Washington DC, December 4, 2022.
7. Panel Member. National Lung Cancer Roundtable: EHR-IT Workshop. Chicago, IL, October 2, 2023.
8. Panel Member. Mid-career discussion. American Society of Preventive Oncology Annual Meeting, Chicago, IL. March 15, 2024.

### ***Invited Webinar presenter***

1. **Wernli KJ**. Patient-centered Outcomes Research. Presented to Cancer Research Network Scholars, July 8, 2014.
2. **Wernli KJ**, Johnson D. Patient and Stakeholder Engagement in Research: Strategies for Initiating Research Partnerships. Invited by Patient-Centered Outcomes Research Institute, July 19, 2017.
3. **Wernli KJ**. Using Optum claims data in US cancer patients: an example in adolescent and young adults. Presenting within in "Connecting the dots: the creation and use of data linkages to study cancer survivorship and health outcomes research." Hosted by American Society for Preventive Oncology Survivorship, Health Outcomes & Comparative Effectiveness Research Special Interest Group, January 8, 2019.
4. **Wernli KJ**, Jordan M. Adapting clinical design principles for public health. Artefact, May 1, 2020.
5. **Wernli KJ**. Working towards representation. Two examples in cancer research. KPWHRI Seminar, November 11, 2020.
6. **Wernli KJ**, Mobley E. Insider insights: Grant writing tips from study section reviewers. Hosted by American Society for Preventive Oncology Survivorship, Health Outcomes & Comparative Effectiveness Research Special Interest Group, August 16, 2023.
7. **Wernli KJ**, Vasavada A. Larch Trial: Patient-Provider Communication (Multilevel interventions to increase adherence to lung cancer screening). NCI Digital Health Administrative Supplement Meeting. October 17, 2024.